Old Dominion University

ODU Digital Commons
Biomedical Sciences Theses & Dissertations

Graduate School Interdisciplinary Programs

Summer 2019

Targeting the Pin Domain of Type II Toxins Is a Novel Approach to
Treat Infections Caused by Nontypeable Haemophilus Influenzae
Ashley Lynne Molinaro
Old Dominion University, asanf003@odu.edu

Follow this and additional works at: https://digitalcommons.odu.edu/
gradschool_biomedicalsciences_etds
Part of the Biology Commons, Microbiology Commons, and the Physiology Commons

Recommended Citation
Molinaro, Ashley L.. "Targeting the Pin Domain of Type II Toxins Is a Novel Approach to Treat Infections
Caused by Nontypeable Haemophilus Influenzae" (2019). Doctor of Philosophy (PhD), Dissertation,
Biological Sciences, Old Dominion University, DOI: 10.25777/cmsb-qk23
https://digitalcommons.odu.edu/gradschool_biomedicalsciences_etds/3

This Dissertation is brought to you for free and open access by the Graduate School Interdisciplinary Programs at
ODU Digital Commons. It has been accepted for inclusion in Biomedical Sciences Theses & Dissertations by an
authorized administrator of ODU Digital Commons. For more information, please contact
digitalcommons@odu.edu.

TARGETING THE PIN DOMAIN OF TYPE II TOXINS IS A NOVEL APPROACH TO
TREAT INFECTIONS CAUSED BY NONTYPEABLE HAEMOPHILUS INFLUENZAE

by
Ashley Lynne Molinaro
B.S. May 2010, Norwich University

A Dissertation Submitted to the Faculty of
Old Dominion University in Partial Fulfillment of the
Requirements of the Degree of
DOCTOR OF PHILOSOPHY
BIOMEDICAL SCIENCES
OLD DOMINION UNIVERSITY
AUGUST 2019

Approved by:
Dayle A. Daines (Director)
Fred C. Dobbs (Member)
Christopher J. Osgood (Member)
Jing He (Member)

ABSTRACT
TARGETING THE PIN DOMAIN OF TYPE II TOXINS IS A NOVEL APPROACH TO
TREAT INFECTIONS CAUSED BY NONTYPEABLE HAEMOPHILUS INFLUENZAE
Ashley Lynne Molinaro
Old Dominion University, 2019
Director: Dr. Dayle A. Daines

Toxin-antitoxin (TA) gene pairs have been identified in nearly all bacterial
genomes sequenced to date and are thought to facilitate persistence and antibiotic
tolerance. TA loci are classified into various types based upon the characteristics of
their antitoxins, with those in type II expressing proteic antitoxins. Many toxins from type
II modules are ribonucleases that maintain a PilT N-terminus (PIN) domain containing
conserved amino acids considered essential for activity. The vapBC (virulence
associated protein) TA system is the largest subfamily in this class and has been linked
to pathogenesis of nontypeable Haemophilus influenzae (NTHi). This dissertation
presents three studies investigating type II TA modules in NTHi. The first study
determined the crystal structure of the VapBC-1 complex. Based on this structure,
aspartate-to-asparagine and glutamate-to-glutamine mutations of four conserved
residues in the PIN domain of VapC-1 were constructed, and the effects of these
mutations on pathogenesis were tested ex vivo. A novel model system was designed
that consisted of an NTHi ΔvapBC-1 strain complemented in cis with the toxin mutants
in tandem with the wild-type antitoxin controlled by the vapBC-1 native promoter in
single copy. This determined that a single mutation to a conserved amino acid in the
PIN domain significantly reduced the survival of NTHi. The second study measured the
induction of a type II antitoxin in trans and the induction of a type II toxin in cis with or

without an E. coli arabinose permease in cis in the background of NTHi. A bioassay was
then designed to investigate the ability of NTHi to transport arabinose, the molecule
necessary to induce the araBAD genes. Lastly, a bioinformatics study was performed
on 12 recently-sequenced clinical isolates of NTHi to determine the conservation of four
vap operons. Seven strains maintained all four operons, the other five strains
maintained three and the operons all shared significant sequence homology. These
three studies provide insight into the importance of the type II TA loci in NTHi and due to
their conservation and contribution to pathogenesis, these modules prove to be
promising candidates for the development of antimicrobial treatments.
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1
OVERVIEW
Haemophilus influenzae was originally called Bacillus influenzae (or Pfeiffer’s
bacillus) by bacteriologist Richard Pfeiffer when it was mistakenly identified as the
causative agent of the 1889 influenza pandemic (1). It was not until the 1920s that the
organism was named H. influenzae (2). It is a Gram-negative obligate commensal of the
upper respiratory tract. H. influenzae is divided into two groups – encapsulated strains
and un-encapsulated or nontypeable strains (NTHi). There are six capsular serotypes,
a-f (3), whose capsular region (cap) all share the same organization (4-7). The cap
locus is comprised of three regions – region I contains the bexDCBA genes which code
for an ATP-driven polysaccharide export apparatus (8), region II contains serotypespecific DNA which distinguishes the six serotypes from each other (9), and region III
contains the hcsAB genes which facilitate transport of the capsular polysaccharide
across the outer membrane (Fig. 1) (10). H. influenzae stereotype b (Hib) strains

FIG 1 Representation of the cap locus in H. influenzae. The polysaccharide capsule in
typeable H. influenzae is controlled by the cap locus for all six serotypes (a-f). Regions I
and III are conserved among serotypes while region II encodes the genes responsible
for the specific polysaccharide synthesis. Region II can vary in the number of genes
responsible for the biosynthesis of each serotype. This figure is adapted from reference
195.
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were most often associated with invasive diseases such as meningitis, cellulitis, and
septicemia, related to a high incidence of morbidity and mortality (11). However, since
the approval of the first Hib conjugate vaccine in 1987, there has been a significant
decrease in disease associated with Hib (12, 13).
H. influenzae is a human-adapted commensal of the upper respiratory tract.
Meningitis caused by Hib has significantly decreased in countries that routinely
vaccinate against the bacterium. However, in developing countries it is estimated that
meningitis affects 7-13 million children under the age of five annually (14). NTHi is the
most common bacterial cause of chronic obstructive pulmonary disease (COPD), which
according to the World Health Organization (WHO), is the third leading cause of death
worldwide (15, 16). NTHi is also a leading cause of recurrent otitis media (OM) in the
pediatric population (17). The financial implications of these three diseases is in the
billions of dollars annually (18-20).
Unfortunately, the Hib vaccine is not effective in preventing infections caused by
NTHi because the conjugate vaccine links a carrier protein to the polyribosylribitol
phosphate (PRP) capsule unique to Hib. Due to the absence of a capsule as well as the
genetic diversity of NTHi (21, 22), a suitable vaccine candidate against infections
caused by NTHi is not available. Consequently, NTHi infections have been on the rise
since the implementation of the Hib vaccine. NTHi strains share a number of virulence
factors such as lipooligosaccharide (LOS), IgA protease, biofilm formation, adhesions,
and other surface structures; however, the heterogeneity of the species makes it
increasingly difficult to develop a vaccine suitable against a large number of isolates
(23). Some of the outer membrane proteins that have been explored as potential
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vaccine candidates include: P1, P2, P4, P6, Tbp1, Tbp2, and protein D (24). Two
vaccines seemed to provide positive results: a ketodeoxyoctanoate (KDO) based
glycoconjugate vaccine elicits a response from the monoclonal antibody 6E4 and binds
to KDO (25). However, susceptible strains would have to express the KDO epitope in
high levels, and in a small study of 33 NTHi strains, only 36% of the isolates were killed
by the anti-KDO antibody (25). Another potential candidate is the protein D conjugate
vaccine. In a clinical trial of nearly 5,000 infants, protective efficacy was reported in 36%
of infants vaccinated with the 10-valent pneumococcal H. influenzae protein D
conjugate vaccine (PHiD-CV) (26). However, a number of studies measured carriage
rates after children were fully vaccinated with the PHiD-CV and found no change in the
rates (27-29).
While a vaccine would be ideal in the race to prevent diseases caused by NTHi,
the antigenic variations among gene products in this species may just be too great for
preparation of an effective vaccine. However, exploiting toxin-antitoxin (TA) modules is
a novel way to treat disease and infections caused by NTHi. TA loci were first identified
on plasmids as modules that aided in plasmid maintenance and stability by mediating
the killing of plasmid-free cells and thereby ensuring stable plasmid inheritance (30, 31).
Following the advent of whole genome sequencing, TAs were found to be maintained in
the chromosomes of numerous Gram-negative and Gram-positive bacterial genera as
well as in the Archaea (32-34). Chromosomally-located TAs have been implicated as
important metabolic regulators in many human pathogens, including Escherichia coli,
nontypeable Haemophilus influenzae (NTHi), Mycobacterium tuberculosis, and
Staphylococcus aureus (35-38). Stressful environmental conditions, such as nutrient
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limitation, heat, pH, and oxidative stress from the host immune response or antibiotic
therapy (39-42), initiate degradation of the labile antitoxin via bacterial proteases such
as Lon and ClpXP (43, 44). After the antitoxin is degraded, the toxin is free to inhibit
essential cellular processes, such as ATP and protein synthesis, DNA replication,
peptidoglycan synthesis, and cell division (45-49), resulting in growth arrest and
facilitating a persister state.
TA modules are operons typically organized with the antitoxin located directly
upstream of the toxin. Six different TA families have been identified and characterized
by the nature of the antitoxin. In type I and type III systems, the antitoxin is an RNA. The
type I antitoxin is antisense RNA that binds the toxin mRNA under normal cellular
conditions, inhibiting its translation (50). Following degradation of the type I antitoxin,
the toxin is translated and depolarizes the cell membrane, thereby inhibiting ATP
synthesis (50, 51). In the type III TA loci, the antitoxin is a pseudoknot RNA that binds to
the protein toxin and prevents it from cleaving RNA (52, 53). Type II, IV, V, and VI
systems all contain protein antitoxins. In type II systems, both the antitoxin and toxin are
proteins that form a non-toxic complex upon translation (54). Many toxins of the type II
TA modules have been characterized as ribonucleases (46, 55). Type IV systems are
unique in that the antitoxin inhibits toxin activity by interacting directly with the targets of
the toxin, which are cytoskeletal proteins necessary for proper cell division (49, 56). The
only type V TA locus described to date is ghoST, in which the antitoxin inhibits the
activity of the toxin by cleaving its mRNA (57). There is one identified type VI locus
currently, designated as socAB. In this module, the antitoxin SocA does not inhibit the
activity of the SocB toxin directly, but rather guides it to the protease ClpXP (58). When
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SocB is not degraded by ClpXP, it binds to DnaN and inhibits DNA replication and
elongation (58). Free-living prokaryotes tend to have more TA loci than obligate
intracellular microorganisms, and pathogenic bacteria often have more TA loci than their
non-pathogenic relatives (59). Maintaining numerous TA loci in their genomes may
increase the ability of microorganisms to rapidly respond to stresses in their
microenvironments, and there is growing interest in studying the contributions of these
systems to microbial pathogenesis and persistence.
Type II TA loci contribute significantly to the survival and virulence of NTHi during
infection (36, 60). With this in mind, this dissertation highlights the use of the newly
solved crystal structure of VapBC-1 from NTHi to study the highly conserved PilT Nterminal (PIN) (61) domain and the implications it has on NTHi survivability in a recently
published human infection model. A novel assay was designed in the background of
NTHi to study the growth arrest and growth recovery of the type II toxin and antitoxin
proteins utilizing IPTG and arabinose-inducible promoters. Lastly, 12 clinical isolates of
NTHi were sequenced and the sequences were used to investigate the conservation
and organization of four conserved type II TA loci maintained in H. influenzae strains.
The conservation of these TA loci in NTHi makes them novel candidates for
antimicrobial therapy.
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CRYSTAL STRUCTURE OF VAPBC-1 FROM NONTYPEABLE HAEMOPHILUS
INFLUENZAE AND THE EFFECT OF PIN DOMAIN MUTATIONS ON SURVIVAL
DURING INFECTION
This chapter is published, and is reprinted here with permission:
Molinaro AL, Kashipathy MM, Lovell S, Battaile KP, Coussens NP, Shen M, Daines DA.
2019. Crystal Structure of VapBC-1 from Nontypeable Haemophilus influenzae and the
Effect of PIN Domain Mutations on Survival during Infection. J Bacteriol 201.

INTRODUCTION
Type II modules are currently the best characterized TAs and the vapBC (virulence
associated protein) system is the largest subfamily in this class, with VapB being the
proteic antitoxin and VapC the ribonuclease toxin. The VapB antitoxin has two roles in
the VapBC system: a region near its C-terminus binds to and neutralizes the toxin, while
its N-terminus binds DNA and increases the TA complex stability in auto-regulating
transcription of its cognate operon (Fig. 2) (62). The VapC toxin contains a conserved
PIN domain that is crucial for its activity (61). While it has been shown that some VapC
homologues are able to target specific RNA in bacterial cells (55, 63, 64), it is important
to note that a VapC toxin has not yet been co-crystallized with its specific RNA target (62).
NTHi maintains two vapBC modules in its chromosome, designated as vapBC-1
and vapBC-2. It has been previously shown that the vapBC-1 locus significantly increases
survival during infection, both in vivo and ex vivo (36). Despite low primary sequence
homology among the VapC toxins from different microorganisms, the PIN domain is
ubiquitous and characterized by highly conserved acidic, polar, and hydrophobic residues
in the active site (62, 65). The VapBC-1 crystal structure was solved with the assistance
of collaborators from the Protein Structure Laboratory at the University of Kansas and the
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Advanced Photon Source at Argonne National Laboratory. Based on the VapBC-1 crystal
structure, directed mutations were introduced to four PIN domain residues and evaluated
the resulting mutant’s protein-protein interactions, effects on the growth of E. coli, and
ability to survive during infections of primary human tissues ex vivo. The results show that
some of the mutations in the PIN domain of the VapC-1 toxin were associated with
decreased toxicity in E. coli, but the mutants retained the ability to homodimerize and to
heterodimerize with the wild-type cognate antitoxin, VapB-1. A new system was designed
and constructed to quantify the effects of these mutations on NTHi survival during
infections of primary human tissues ex vivo. Any mutation to a conserved amino acid in
the PIN domain significantly decreased the number of survivors compared to that of the
in cis wild-type toxin under the same conditions.
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FIG 2 Model of TA locus function and inhibition of the toxin with a small molecule. Under
stressful conditions, the antitoxin is degraded, freeing the toxin to cleave mRNA,
resulting in bacterial growth arrest. Small molecules that inhibit the activity of the toxin
VapC-1 would prevent growth arrest, thereby facilitating the complete clearance of a
bacterial infection when used in conjunction with antibiotic therapy. This figure is
adapted from reference 84.
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RESULTS
Structural analysis of VapBC-1. Although VapBC structures from other
organisms have been determined (66), the structure of VapBC-1 from NTHi has not been
reported. Therefore, the crystal structure of VapBC-1 was determined from a
polyhistidine-tagged construct that allowed the VapB-1 antitoxin to be co-expressed with
the VapC-1 toxin. The primary sequences of the purified toxin and antitoxin used for
crystallization are shown in Fig. 3.

FIG 3 Primary sequence of the VapBC-1 complex used for crystallization screening.
(A) VapB-1 and (B) VapC-1. The underlined residues are from the pET24b cloning
vector.
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The overall structure of NTHi VapC-1 adopts an -β- sandwich fold in which five
central β-strands are flanked by two -helical regions typically observed for PIN-like
domains (Fig. 4A). Subunits of VapC-1 form a dimer in which the hydrophobic surfaces
of helices 3 and 5 are positioned approximately 10 Å from one another (Fig. 5A). The
active site residues D6, E43, D99 and E120, depicted as spheres in Fig. 5A, are
conserved amongst various VapC species and adopt a similar spatial arrangement
relative to previously determined structures. The main network of hydrogen bonds is
formed between dimer subunits through residues Y81 in helix 5 and N97, N98 and W101
of helix 6 (Fig. 5B). An additional hydrogen bond is present between E75 of subunit B
and Y41 in helix 3 of subunit A. The reciprocal interaction, E75 in subunit A with Y41 of
subunit B, is not observed as the side chains are positioned 5 Å apart. Thus, this hydrogen
bond interaction is not likely a critical interaction between dimer subunits. Similar to
previously determined structures (62, 67), the VapC-1 dimer has an interface area of
1,024 Å2, a solvation free energy gain from dimer formation (ΔGint) of -21.6 kcal/mol and
13% of the accessible surface area buried as determined with PISA (68). As noted above,
there is minimal hydrogen bonding between the dimer subunits and no salt bridge
interactions are present.
The VapC-1 dimer adopts a similar arrangement compared to structures from other
organisms (Fig. 6). Comparison of the NTHi VapC-1 dimer with homologous structures,
identified from a PDBeFold search (69) yielded RMS deviations between C-atoms of
1.85 Å (251 residues, VapC D98N from Shigella flexneri, PDB 5ECD) (70), 1.85 Å (253
residues, VapBC from S. flexneri, PDB 3TND) (71) and 1.79 Å (256 residues, VapBC
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FIG 4 Structure of the H. influenzae VapC-1 monomer subunit. (A) Colored by
secondary structure with -helices (green) and β-sheets (magenta). (B) Primary and
secondary structural elements of VapC-1. Conserved active site residues are indicated
by the red arrows.
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FIG 5 Structure of the H. influenzae VapC-1 dimer showing subunits A and B in
magenta and cyan, respectively. (A) View along the 2-fold axis of the dimer. Helices that
form the interacting surfaces between subunits are indicated. Conserved active site
residues are rendered as spheres. Note that E120 (chain A) was partially disordered so
all of the side chain atoms were not modeled. (B) Hydrogen bond interactions (dashed
lines) between residues of the dimer.
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from Rickettsia felis in complex with DNA, PDB 3ZVK) (72). The main difference is
observed in helix 2 which is moved further away from helix 1 in the NTHi VapC-1 dimer
as noted in panel A of Fig. 6. As shown below, this relative difference in the position of
helices 1-2 is necessary to accommodate VapB-1 binding. Slightly lower RMS
deviations were observed when comparing single subunits and superposition with VapC1 (subunit A) yielded the following: 5ECD (subunit A, 1.48 Å, 126 residues), 3TND
(subunit C, 1.37 Å, 129 residues) and 3ZVK (subunit A, 1.54 Å, 131 residues). The main
conformational differences occur in the relative positions of helices 1-2 as was
observed for superposition of the dimers noted above.
The VapB-1 portion of the NTHi VapBC-1 complex could be modeled from M1 to
P72 (subunit C) and M1 to D69 (subunit D). The overall structure of VapB-1 consists of a
ribbon-helix-helix motif in which the four β-sheets of the N-terminus dimerize with another
subunit to form a β-barrel type architecture (Fig. 7). As determined using PISA (68),
extensive hydrogen bonding and salt bridge interactions are present between the dimer
subunits (27 and 11 respectively) which forms an interface area of 1,662 Å 2 and a
solvation free energy gain of -17.0 kcal/mol. Notably, 25% of the accessible surface area
is buried to form the dimer interface. The C-terminus contains a long stretch of flexible
residues occupied by two -helices that bind to the VapC-1 toxin forming a 1:1 interaction
between VapB-1 and VapC-1 subunits. A similar architecture is observed for other VapBC
structures, such as VapBC from R. felis in complex with DNA (PDB 3ZVK). The
dimerization core regions are quite similar. However, the VapC-1 binding region of the Cterminus adopts a markedly different orientation relative to the VapB-1 β-barrel dimer
core. This is not too surprising, given that VapBC complexes often adopt various
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FIG 6 Comparison of the H. influenzae VapC-1 dimer (magenta/cyan) with the VapC
dimer from homologous structures. (A) VapC D98N (coral) from Shigella flexneri (PDB
5ECD); (B) VapBC (gold) from Shigella flexneri (PDB 3TND); (C) VapBC (green) from
Rickettsia felis in complex with DNA (DNA not shown) (PDB 3ZVK).

15

FIG 7 Structure of the H. influenzae VapB-1 dimer showing subunits C (gold) and D
(blue). Secondary structure elements annotated for subunit C. (A) Perpendicular view;
(B) view along the β-barrel axis; (C) primary and secondary structural elements of
VapB-1.
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quaternary structural arrangements that produce higher order oligomers (62).
Although the toxin:antitoxin form commonly observed consists of 1:1 interactions
between subunits, the quaternary arrangement resulting from the binding of NTHi VapB1 to VapC-1 in this structure appears to be unique. As shown in Fig. 8A, the asymmetric
unit consists of a VapB-1 and VapC-1 dimer in which the C-terminal helices of VapB-1
(subunit C) occupy a cleft formed by 1-4 of VapC-1 (subunit A). Subunit B of VapC-1
forms a similar interaction with VapB-1 (subunit D). However, this interaction is with a
VapB-1 molecule related by crystallographic symmetry (Fig. 8B) and creates tightly
packed pairs of VapB-1 and VapC-1 dimers (Fig. 8C). This arrangement results in a row
of alternating VapB-1 and VapC-1 dimers.
As noted above, the C-terminal tails of VapB-1 are positioned within a cleft formed
by 1-4 of a VapC-1 dimer. Specifically, the C-terminal tail spanning P41-P72 (subunit
C) and P41-D69 (subunit D) of VapB-1 (Fig. 9A) position the -helices within a
complementary cleft of VapC-1 subunits A and B respectively (Fig. 9B). The binding
interface between VapB-1 and VapC-1 is 1,385 Å2 with a solvation free energy gain of
-21.8 kcal/mol. The majority of the hydrogen bond and salt bridge interactions occur at
the C-terminus of VapB-1 spanning residues A66 to L70 (Fig. 10). Notably, R67 of VapB1 interacts with E43 and D99 of VapC-1, which are conserved catalytic residues along
with D6 and E120, amongst various VapC species (73). Similar interactions were
observed for the S. flexneri VapBC structure (PDB 3TND), suggesting a similar mode of
VapC-1 inhibition. Additional hydrogen bond interactions are observed between G55 and
N52 of VapB-1 and N56 and N52 of VapC-1 (not shown).
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FIG 8 Structure of VapBC-1 with VapB-1 subunits C/D (gold/blue) and VapC-1 subunits
A/B (magenta/cyan). (A) Asymmetric unit showing the positioning of the C-terminal tail
of VapB-1 (subunit C) occupying the cleft formed by 1-4 of VapC-1 (subunit A); (B)
asymmetric unit with an extra VapB-1 dimer related by crystallographic symmetry
(VapB-1′); (C) same as that shown in panel B but rendered as a surface.
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FIG 9 Binding of VapB-1 to VapC-1. (A) Zoomed-in view of Fig. 5B showing the binding
of the C-terminal tail of VapB-1 subunit C residues P41to P72 (gold) and subunit D
residues P41-D69 (blue) bound to the VapC-1 dimer; (B) electrostatic surface of VapC-1
subunit A showing the binding of the C-terminal -helices of VapB-1 (P41-P72, gold)
positioned within the cleft form by 1-4 of VapC-1.
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FIG 10 Hydrogen bond interactions between the C-terminal end of VapB-1 subunit C
(gold) and VapC-1 subunit A (magenta).
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Protein-protein interactions in vivo. Proteins encoded by type II TA modules
form nontoxic heterocomplexes of the antitoxin and toxin homodimers under normal
growth conditions in vivo (66). In order to examine antitoxin and toxin homodimer
formation and heterodimerization, a bacterial LexA-based system (74) was employed.
The LexA repressor consists of two domains, a DNA-binding domain (DBD) and a
dimerization domain. The DBD can function as a transcriptional repressor only in
dimeric form. Other domains can be fused in-frame to the DBD and will restore the
repressor's function only if they interact (75). If the fused proteins interact, the lacZ
reporter gene is repressed, reducing beta-galactosidase activity, which is quantitated
biochemically as dimensionless Miller units (76). Strong protein-protein interactions
result in minimal beta-galactosidase activity, whereas weak interactions result in
significant activity.
This system was applied to evaluate the ability of VapC-1 single and double sitedirected mutants to interact with the wild-type VapB-1 antitoxin (heterodimerization) as
well as with themselves (homodimerization) in vivo. The homodimerization of the wildtype VapC-1 toxin was not evaluated due to its substantial toxicity when overexpressed
from a high copy number plasmid. Table 1 shows that the VapC-1 mutants retained the
ability to homodimerize with comparative strengths of interaction of E120Q > D6N > E43Q
D99N > E43Q > D99N > D6N D99N. Mutant or wild-type VapC-1 toxins could
heterodimerize with wild-type VapB-1, at relative levels of D6N > D6N D99N > E43Q
D99N > E120Q > WT > E43Q > D99N (Table 2).
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TABLE 1 Homodimerization of VapC-1 mutants
Homodimerizationa of LexA DBD
fusion in SU101 (Miller units)
Construct

Avg

± SD

pSR658 (control)

1302.6

78.2

VapC-1 D6N

38.5

12.9

VapC-1 D99N

59.5

9.4

VapC-1 D6N D99N

148.3

24.8

VapC-1 E43Q

55.5

9.8

VapC-1 E43Q D99N

39.2

2.2

VapC-1 E120Q

27.6

8.4

aThe

homodimerization of the wild-type VapC-1 toxin was not evaluated due to its
substantial toxicity when overexpressed in high copy.

TABLE 2 Heterodimerization of VapC-1 mutants with the wild-type VapB-1 antitoxin
Heterodimerization of LexA
DBD fusions in SU202 (Miller
Units)
Construct

Avg

± SD

Control vectors

1813.4

130.0

VapC-1 D6N

37.9

11.5

VapC-1 D99N

360.5

30.6

VapC-1 D6N D99N

56.0

6.0

VapC-1 E43Q

202.2

18.9

VapC-1 E43Q D99N

113.3

5.5

VapC-1 E120Q

167.3

11.6

VapC-1 Wild-type

190.4

6.4
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VapC-1 activity in vivo. A growth-recovery assay was used to evaluate VapC-1
activity in E. coli. Mutant or wild-type VapC-1 toxins were individually cloned under the
control of the PBAD promoter and induced with 3.3 mM (0.05% wt/vol) L-arabinose (77).
The wild-type VapB-1 antitoxin was under the control of the Ptrc promoter and its
expression was induced with 0.5 mM IPTG (78). Thus, VapC-1 and VapB-1 could be
induced either independently or simultaneously from compatible plasmids that are cotransformed and expressed in the same E. coli strain, LMG194. To initiate the assay, a
culture in early growth phase was split and treated with either: (i) media only, (ii)
arabinose-only, (iii) IPTG-only, or (iv) both arabinose and IPTG. Typically, significant
growth arrest occurs at approximately 70 min after wild-type VapC-1 was induced, but
this was not observed if the antitoxin is expressed alone (Fig. 11A, red and green
symbols, respectively). If VapB-1 and VapC-1 were co-induced, the antitoxin inhibited the
toxin ribonuclease activity and growth was similar to the non-induced control (Fig. 11A,
purple and blue symbols, respectively). The results of experiments with the VapC-1
mutants are presented in Fig. 11B-G. Significantly attenuated growth was observed upon
induction of VapC-1 in strains with the wild-type, D99N and E120Q mutant toxins (red
symbols in Fig. 11A, C, and G, respectively), compared to the growth observed when
VapB-1 was co-induced (purple diamonds). However, the VapC-1 D6N, D6N D99N,
E43Q, and E43Q D99N mutants did not cause significant growth arrest when induced in
vivo (Fig. 11B and D to F, red symbols).
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FIG 11 E. coli growth-recovery assays with inducible wild-type or mutant VapC-1 toxins.
(A) Non-induced E. coli growth (measured by absorbance at 595 nm) or growth
following induction of wild-type (WT) VapC-1, VapB-1, or both WT VapC-1 and VapB-1.
(B to G) Similar growth experiments were performed with the VapC-1 D6N (B), D99N
(C), D6N D99N (D), E43Q (E), E43Q D99N (F), and E120Q (G) mutants. All data are
plotted as mean ± SD of the result of three biological replicates in triplicate. Statistical
comparisons of growth following WT or mutant VapC-1 inductions against the
corresponding non-induced controls were made using the repeated-measures ANOVA.
The significance of the results were as follows: VapC-1 WT P < 0.0001 (A); D6N mutant
P = 0.21 (B); D99N mutant P = 0.0015 (C); D6N D99N mutant P = 0.15 (D); E43Q
mutant P = 0.39 (E); E43Q D99N mutant P = 0.28 (F); E120Q mutant P = 0.017 (G).
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FIG 11 Continued.
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Construction of an in cis ectopic system to study TA modules. The growth
recovery assay in E. coli strain LMG194 is a valuable tool to evaluate the effects of toxin
and antitoxin expression. However, the antitoxin and toxin proteins are cloned into
separate multi-copy vectors to allow independent expression and are controlled by
artificial promoters. Therefore, the assay does not allow either expression via the native
transcriptional regulation of the locus or the characterization of a mutant locus in single
copy on the chromosome. To evaluate these aspects, a novel system was developed that
consisted of the native vapBC-1 promoter controlling an operon containing the wild-type
vapB-1 gene followed by either the wild-type or each mutant vapC-1 gene (Fig. 12). This
system mimics the natural sequential arrangement and copy number of the operon. The
module is flanked by homologous regions of the metE pseudogene from NTHi strain 86028NP (NTHI_RS09270, an authentic frameshift resulting in a deletion of over 100 amino
acids) which targets the reconstructed TA locus to a chromosomal region that is not in
use. Briefly, fusions are amplified by PCR, used to transform NTHi, and are homologously
recombined into the chromosome at the NTHI_RS09270 pseudogene site in single copy.
NTHi is an obligate human parasite with natural deletions in many genes involving
metabolism. Since it scavenges a number of essential molecules from its host, this results
in the requirement to supplement growth media in vitro but not in vivo or ex vivo (79-81).
The well-characterized 86-028NP ΔvapBC-1 strain (36) was chosen as the background
to analyze each tandem fusion to eliminate contributions by the wild-type vapBC-1 locus.
This novel approach is the most biologically relevant system currently available to study
the effects of TA locus mutants in the background of NTHi.
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To ensure that the in cis mutant modules had no effect on the replication of strains,
the growth of the reconstructed wild-type, vapBC-1 mutants, and the parent strain 86028NP ΔvapBC-1 was measured over 7 h. There were no significant differences in growth
among the strains (data not shown), supporting the use of this model to investigate
variations in pathogenesis attributable to mutations in VapC-1.

FIG 12 NTHi_RS09270 delivery vector for single-copy in cis expression of cloned
genes. This construct targets the metE pseudogene in strain 86-028NP. The native
vapBC-1 promoter controls either the wild-type vapBC-1 operon or an engineered
operon consisting of the wild-type vapB-1 antitoxin and one of the vapC-1 mutated
toxins.

Effect of VapC-1 mutations on survival of NTHi in primary human tissues.
The EpiAirway model (AIR 100 ABF, MatTek, Ashland, MA, USA), which consists of
antibiotic-free primary human respiratory epithelial tissue at the air-liquid interface, was
used to evaluate the impact of VapC-1 mutations on NTHi survival during infections. After
co-culturing the in cis complemented strains with EpiAirway tissues in antibiotic-free
media for 48 h, the tissues were treated with 100 µg/ml gentamicin for 90 min to kill any
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NTHi not internalized, as this antibiotic does not enter the tissues. The surviving
internalized bacteria were recovered, diluted and plated for viable colony counts. This
experiment was performed with n = 6 tissues originating from at least two different
EpiAirway kits. The survival of all strains containing VapC-1 mutants were significantly
reduced compared to the strain containing wild-type toxin (Fig. 13). The survival of the
parent strain, 86-028NP ΔvapBC-1, was also significantly decreased, as previously
reported (36).
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FIG 13 Number of viable CFU/milliliter of NTHi in cis-complemented mutants or the wildtype operon in primary human tissues at the air-liquid interface. EpiAirway tissues were
infected at ~ 1.0 x 104 CFU per insert with either the 86-028NP ΔvapBC-1 deletion
strain, the 86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (wild-type)
strain, the 86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (D6N) strain,
the 86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (D99N) strain, the
86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (D6N D99N) strain, the
86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (E43Q) strain, the 86028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (E43Q D99N) strain, the 86028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (E120Q) strain, or the 86028NP ΔvapBC-1 parent strain. At 48 h after infection, gentamicin-resistant bacteria
were harvested for colony counts. Data are expressed as the mean ± SD of six
biological replicates in quadruplicate. All in cis mutants and the parent strain were
significantly attenuated for survival compared to the strain carrying the wild-type VapC-1
in cis. An asterisk denotes a P of ≤ 0.05.

29
DISCUSSION
The VapC-1 toxin of NTHi is an efficient and highly active ribonuclease, and the
vapBC-1 locus is crucial for survival during infection, both ex vivo in primary human
tissues, and in vivo in the chinchilla model of acute otitis media (36). The PIN domain of
VapC homologues has been implicated in the binding and cleavage of RNA substrates
(70) and many acidic residues in this domain are highly conserved (73). Other studies
have evaluated various mutations to the PIN domain (82, 83), and it was previously
demonstrated that the VapC-1 D99N mutant had significantly reduced ribonuclease
activity, while retaining the ability to bind VapB-1 (84).
The NTHi VapBC-1 structure provides insight into heterodimeric interactions and
enables comparisons with VapBC complexes from other organisms. Overall, the VapBC1 homodimer subunits are similar to other reported VapB and VapC structures, adopting
similar protein:protein interactions with the VapB C-terminal helices occupying clefts
within VapC dimers. The homodimer subunits in VapBC complexes often form higher
order oligomers such as heterotetramers, heterohexamers and heteroctamers (62).
Interestingly, the VapBC-1 complex does not adopt any of these higher order quaternary
structures but instead forms a unique linear array of alternating VapB and VapC dimers.
Based on the crystal structure of VapBC-1, two highly conserved aspartate and
two glutamate residues in the toxin PIN domain were mutated to their beta-amino
derivatives, asparagine and glutamine. Analyses of these mutant constructs indicated
decreased ribonuclease activity in vivo measured by growth-recovery assays, and
decreased survival during ex vivo infections of primary human tissues compared to the
wild-type toxin when expressed in the background of NTHi using a novel single-copy in
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cis system. This study also found that the effect of these mutations were not necessarily
additive, as although a VapC-1 D99N mutant was significantly attenuated when
overexpressed in E. coli growth-recovery assays, a double D6N D99N mutation was not.
Interestingly, all VapC-1 mutants were able to strongly homodimerize as well as to bind
wild-type VapB-1, suggesting that the module’s quaternary structure is somewhat
decoupled from the enzymatic activity of the toxin.
The results reported here support the notion that VapBC-1 (and TA modules in
general) have evolved a number of mechanisms to maintain their activity and that their
presence confers a significant advantage to the microorganism. Many studies have linked
TA modules to the survival of bacterial pathogens in host tissues (36, 85-89). Achieving
and maintaining persistence during an infection is central for both successfully evading
the immune response and for nonspecific antibiotic tolerance, leading to a pathogen’s
survival of clinical therapy. This characteristic can substantially contribute to recurrent or
chronic infections and implicates TA modules as therapeutic targets. Indeed, when the
effects of the toxin mutations on NTHi survival inside primary human respiratory tissues
ex vivo were tested, it was found that any perturbation of the acidic residues in the
conserved PIN domain negatively affected survival compared to the wild-type toxin under
the same conditions. These data suggest that targeting any of these individual residues
in the toxin could potentially result in significantly decreasing the survival of NTHi during
infection, and imply that small molecule inhibitors could be most effective in this approach.
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MATERIALS AND METHODS
Bacterial strains and culture conditions. The bacterial strains and plasmids
used in these studies are listed in Table 3. E. coli strains were grown in LB broth or agar
with or without 100 µg/mL ampicillin, 250 µg/ mL erythromycin, 20 µg/mL
chloramphenicol, 30 µg/mL of kanamycin, or 12 µg/mL tetracycline, as required. NTHi
strains were grown in brain heart infusion broth or agar supplemented with 10 μg/mL
heme-histidine and 10 μg/mL β-NAD (sBHI), or on chocolate agar with 5 U/mL bacitracin.
NTHi were routinely cultured at 37 °C with 5% CO2. To construct the ectopic strains,
transformants were selected on chocolate agar plates with 5 μg/mL erythromycin, and
single colonies were passaged for 3 days on selection plates before being confirmed by
DNA sequencing of PCR amplified purified genomic DNA.
Site-directed mutagenesis of VapC-1. VapC-1 D6N and D99N mutants cloned
in tandem with a wild-type VapB-1 in the vector pET24b (Millipore Sigma, Burlington, MA
USA) were previously described (84). These constructs were used as templates for
plasmid expression sets. Synthetic constructs of VapC-1 with E43Q, E120Q, and E43Q
D99N mutations were generated in tandem with wild-type VapB-1 by Eurofins (Eurofins
Genomics, Louisville, KY USA). The VapC-1 D6N D99N construct, also in tandem with
the wild-type VapB-1, was produced by Genscript (Piscataway, NJ USA). Each construct
was confirmed by DNA sequencing (Eurofins Genomics, Louisville, KY USA) following
sub-cloning into the vectors listed in Table 3.
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TABLE 3 Bacteria, plasmids and primers used in this study
Strains

Description

Source

DH5α

F– Φ80lacZΔM15 Δ(lacZYA-argF)
U169 recA1 endA1 hsdR17 (rK–,
mK+) phoA supE44 λ– thi-1 gyrA96 relA1

Laboratory
collection

LMG194

F- ΔlacX74 galE thi rpsL ΔphoA (PvuII) Δara714
leu::Tn10

Invitrogen

SU101

lexA71::Tn5(Def) sulA211 Δ(lacIPOZYA)169/F’ lacIq
lacZ M15::Tn9

M. GrangerSchnarr

SU202

lexA71::Tn5(Def) sulA211 Δ(lacIPOZYA)169/F’ lacIq
lacZ M15::Tn9

M. GrangerSchnarr

86-028NP ΔvapBC-1

Strain 86-028NP with the vapBC-1 locus deleted

(36)

Plasmids

Description

Source

pBAD33

Highly regulated expression vector

(77)

pET24b

Regulated expression vector with His tag

Novagen

pBluescript SK(+)

Cloning vector

(36)

pSR658

WT LexA DBD fusion vector

(74)

pSR659

Mutant LexA DBD fusion vector

(74)

pSR660

WT LexA DBD fusion vector

(74)

pSR661

Mutant LexA DBD fusion vector

(74)

pDD686

vapBC-1 in pET24b

(46)

pDD757

vapBC-1 (vapC-1 D6N) in pET24b

Unpublished

pDD758

vapBC-1 (vapC-1 D99N) in pET24b

(84)

pDD866

vapB-1 in pSR658

(36)

pDD935

vapB-1 in pTrcHisA

Unpublished

pDD946

vapC-1 in pBAD33

Unpublished

pDD1058

5’ end of NTHI_RS09270 in pBluescript SK(+)

This work

pDD1063

3’ end of NTHI_RS09270 in pDD1058

This work

pDD1118

vapBC-1 (vapC-1 D6N D99N) in pUC57

Genscript

pDD1119

vapC-1 D6N D99N in pBAD33

This work

pDD1120

vapC-1 D99N in pSR658

This work
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TABLE 3 Continued
Plasmids

Description

Source

pDD1123

vapC-1 D99N in pSR659

This work

pDD1126

vapC-1 D6N in pSR661

This work

pDD1128

vapC-1 D6N D99N in pSR661

This work

pDD1132

vapC-1 D6N in pBAD33

This work

pDD1133

vapC-1 D99N in pBAD33

This work

pDD1140

NTHI_RS09270-targeted delivery vector

This work

pDD1150

vapC-1 in pSR659

This work

pDD1152

vapC-1 D6N in pET24b

This work

pDD1153

vapC-1 D99N in pET24b

This work

pDD1154

vapC-1 D6N D99N in pET24b

This work

pDD1155

pDD1140 with the native vapBC-1 promoter

This work

pDD1159

pDD1155 with vapB-1vapC-1 D6N

This work

pDD1160

pDD1155 with vapB-1vapC-1 D99N

This work

pDD1161

pDD1155 with vapB-1vapC-1 D6N D99N

This work

pDD1165

vapBC-1 (vapC-1 E43Q) in pCR2.1

Eurofins

pDD1166

vapBC-1 (vapC-1 E120Q) in pCR2.1

Eurofins

pDD1167

pDD1155 with vapB-1vapC-1 E43Q

This work

pDD1168

pDD1155 with vapB-1vapC-1 E120Q

This work

pDD1169

pDD1155 with vapB-1vapC-1 wild-type

This work

pDD1170

vapC-1 E43Q in pSR658

This work

pDD1173

vapC-1 E43Q in pET24b

This work

pDD1174

vapC-1 E120Q in pBAD33

This work

pDD1175

vapC-1 E43Q in pBAD33

This work

pDD1177

vapC-1 E120Q in pSR658

This work

pDD1178

vapC-1 E43Q in pSR659

This work

pDD1179

vapC-1 E120Q in pSR659

This work

pDD1194

vapC-1 E43Q D99N in pBAD33

This work

pDD1196

vapC-1 E43Q D99N in pBAD/Myc-HisA

This work
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TABLE 3 Continued
Plasmids

Description

Source

pDD1199

vapC-1 E43Q D99N in pSR658

This work

pDD1200

vapC-1 E43Q D99N in pSR659

This work

pDD1204

pDD1155 with vapB-1vapC-1 E43Q D99N

This work

Primers

Description

D6NFor

[Phos]AACACCAATATCATTATTTATTTAATG

IDT

D6NRev

[Phos]TAACATATAAATCATAAATTTTCTCG

IDT

321LexFor

GAGGGAGCTCATGCTTACTAAAGTG

IDT

321LexRev

AACAGGTACCTCATAAATTTTCTCG

IDT

322LexFor

GAGAGAGCTCATGATTTATATGTTAG

IDT

322LexRev

TCAGGGTACCCTATTTTGTCCAATCTTGCC

IDT

pETD6NC1SacFor

AAAAGAGCTCTATGATTTATATGTTAAACACC

322Rev

TCAGAAGCTTCTATTTTGTCCAATCTTGCC

IDT

pBAD86C1SacFor

TTACGAGCTCAGGAGCGAGAAAATTTATG

Eurofins

XLacIFor

GTCATCTAGAAAACGCGCGAGGCAGC

Eurofins

XHisRev

TATTTGTCTAGAGGCAGTTCCCTACTCTCG

Eurofins

86C1NdeD6NFor

AAACATATGATTTATATGTTAAACAC

Eurofins

VapCXhoRev

GAATCTCGAGTTTTGTCCAATCTTGCC

Eurofins

86C1NdeFor

AAAACATATGATTTATATGTTAGAC

Eurofins

PermCSpeFor

AAATACTAGTAACACACACGCCATTCC

Eurofins

ErmCSpeRev

GTTAACTAGTGCAGTTATGCATCC

Eurofins

BC1PromBamFor

ACTAGGATCCATCATTTACTCATTGACTTGC

Eurofins

BC1PromNdeRev

TAAGCATATGTACCCTCTCGTATATAC

Eurofins

86B1NdeFor

GGTACATATGCTTACTAAAGTG

Eurofins

2009-1SacFor

TGCCGAGCTCGCAGGTAAGATGTCG

Eurofins

2009-1XbaRev

AAAATCTAGAGATGCACGTGCAACC

Eurofins

2009-2XhoFor

AAAACTCGAGGCTTGCATCTAATGC

Eurofins

2009-2KpnRev

AAAAGGTACCTCACTATCTTGTGCC

Eurofins

Source

Eurofins
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Purification of VapC-1 for crystallization studies. To overexpress VapBC-1
for purification, pDD686 in BL21(DE3) (46) was grown to logarithmic phase at 37 °C
with shaking, induced for 18 h with 1 mM IPTG at 26 °C and harvested at 2,500 x g into
pellets from 25 mL aliquots. After one freeze-thaw cycle, VapBC-1 was isolated in
accordance with the MagneHis protein purification system (Promega, Madison, WI
USA) with the following exceptions: the lysis solution was 1X BugBuster protein
extraction reagent (Millipore Sigma, Burlington, MA USA) with 100 mM HEPES pH 7.2,
300 mM NaCl, 1X ProteCEASE-50 (EDTA-free), and 2 µL/mL RNase-free DNase
(Thermo Fisher Scientific, Waltman, MA USA); the wash buffer contained 100 mM
HEPES pH 7.2 , 300 mM NaCl and 20 mM imidazole, and the elution buffer contained
100 mM HEPES pH 7.2, 300 mM NaCl and 500 mM imidazole. 1 µg of purified VapBC1 was separated on a Bolt precast 4-12% polyacrylamide gel and analyzed via Western
blot using the iBlot and iBind system (Thermo Fisher Scientific, Waltman, MA, USA).
The nitrocellulose blot was probed with a monoclonal anti-His tag primary antibody
(THE anti-His, Genscript, Piscataway, NJ USA), goat anti-mouse IgG-HRP secondary
antibody (Genscript, Piscataway, NJ USA), detected with SuperSignal West Dura
chemiluminescence substrate (Thermo Fisher Scientific, Waltman, MA, USA) and
imaged on a UVP BioSpectrum 815 (UVP LLC., Upland, CA USA).
Crystallization and data collection. A purified preparation of the NTHi VapBC-1
protein complex was concentrated to 20 mg/mL in 20 mM NaCl, 10 mM HEPES pH 7.2
for crystallization screening. All crystallization experiments were set up using an NT8 drop
setting robot (Formulatrix Inc.) and UVXPO MRC (Molecular Dimensions) sitting drop
vapor diffusion plates at 18 °C. 100 nL of protein and 100 nL of crystallization solution
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were dispensed and equilibrated against 50 µL of the latter. Crystals approximately 100
µm long that displayed a needle morphology were observed within one week from the
Proplex screen (Molecular Dimensions) condition C3 (20% [wt/vol] PEG 4000, 100 mM
sodium acetate pH 5.0, 200 mM ammonium acetate). A cryoprotectant solution composed
of 80% crystallization solution and 20% (vol/vol) PEG 200 was dispensed (2 uL) onto the
drop, crystals were harvested with a cryoloop immediately and stored in liquid nitrogen.
X-ray diffraction data were collected at the Advanced Photon Source beamline 17-ID
using a Dectris Pilatus 6M pixel array detector.
Structure solution and refinement. Intensities were integrated using XDS (90,
91) via Autoproc (92) and the Laue class analysis and data scaling, using two data sets
to increase the multiplicity, were performed with Aimless (93) which indicated that the
crystals belong to the mmm Laue class. Structure solution was conducted by molecular
replacement with Morda (94) to place a VapC-1 dimer using Shigella flexneri VapC (PDB
5ECD) as the template and the top solution was obtained in the space group P212121.
The VapC-1 coordinates from Morda were input as a fixed solution into Phaser (95) and
a VapB monomer from the Rickettsia felis VapBC structure (PDB 3ZVK) was used as a
search model. The final solution from Phaser consisted of a VapB-1 and VapC-1 dimer in
the asymmetric unit and the model was improved by automated building with Arp/wARP
(96). Further refinement and manual model building were conducted with Phenix (97) and
Coot (98), respectively. Disordered side chains were truncated to the point for which
electron density could be observed. Structure validation was conducted with Molprobity
(99) and figures were prepared using the CCP4MG package (100). Structure
superposition was carried out with GESAMT (101). Crystallographic data are provided in
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Table 4. Coordinates and structure factors were deposited to the worldwide Protein Data
Bank (wwPDB) with the accession code 6NKL.
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TABLE 4 Crystallographic data for VapBC-1
Parameter

Value(s) for VapBC-1

Data Collection
Unit-cell parameters (Å, o)
Space group

a=43.88, b=57.32, c=175.75
P212121

Resolution (Å)a

48.01-2.20 (2.28-2.20)

Wavelength (Å)

1.0000

Temperature (K)

100

Observed reflections

303,859

Unique reflections

23,388

<I/(I)>a

10.9 (2.1)

Completeness (%)a

100 (100)

Multiplicitya

13.0 (13.7)

Rmerge (%)a,b

16.8 (161.3)

Rmeas (%)a,d

17.5 (167.7)

Rpim (%)a,d

4.9 (45.2)

CC1/2 a,e

0.998 (0.784)

Refinement
Resolution (Å)a
Reflections (working/test)a
Rfactor / Rfree (%)a,c
No. of atoms (VapB/VapC1/Water)

48.01-2.20
22,146/1,166
18.6/23.4
1,085 / 2,103 / 58

Model Quality
R.m.s deviations
Bond lengths (Å)

0.009

Bond angles (o)

0.981

Average B-factor (Å2)
All Atoms

43.5
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TABLE 4 Continued
Parameter

Value(s) for VapBC-1

Data Collection
VapB-1

48.0

VapC-1

41.3

Water

41.8

Coordinate error

0.24

(maximum likelihood) (Å)
Ramachandran Plot

aValues

Most favored (%)

96.8

Additionally allowed (%)

3.0

in parenthesis are for the highest resolution shell.
= hkli |Ii(hkl) - <I(hkl)>| / hkli Ii(hkl), where Ii(hkl) is the intensity measured for
the ith reflection and <I(hkl)> is the average intensity of all reflections with indices hkl.
cRfactor = 
hkl ||Fobs (hkl) | - |Fcalc (hkl) || / hkl |Fobs (hkl)|; Rfree is calculated in an identical
manner using 5% of randomly selected reflections that were not included in the
refinement.
dRmeas, redundancy-independent (multiplicity-weighted) Rmerge (93, 102); Rpim, precisionindicating (multiplicity-weighted) Rmerge (103).
eCC1/2 is the correlation coefficient of the mean intensities between two random halfsets of data (104, 105).
bRmerge
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Cloning and protein-protein interactions of VapC-1 mutants. The VapC-1
D99N, E43Q, E43Q D99N, and E120Q mutants were cloned by amplifying the vapC-1
D99N gene from pDD758, the vapC-1 E43Q gene from pDD1165, the vapC-1 E43Q
D99N gene from pDD1196, or the vapC-1 E120Q gene from pDD1166 using high-fidelity
Phusion Flash DNA Polymerase (Thermo Fisher Scientific, Waltham, MA USA) and the
primers 322LexFor and 322LexRev. The PCR products, pSR658, and pSR659 were
digested with SacI and KpnI prior to ligation, resulting in pDD1120, pDD1123, pDD1170,
pDD1178 pDD1199, pDD1200, pDD1177, and pDD1179. VapC-1 D6N and D6N D99N
were cloned by amplifying the vapC-1 D6N gene from pDD757 and the vapC-1 D6N D99N
gene from pDD1118, using high-fidelity Phusion Flash DNA Polymerase with
pETD6NC1SacFor and 322LexRev primers. The PCR products, pSR660, and pSR661
were digested with SacI and KpnI prior to ligation, resulting in pDD1125, pDD1126,
pDD1129, and pDD1128. The wild-type VapC-1 toxin was cloned into pSR659 with the
above method from NTHi strain 86-028NP genomic DNA (pDD1150). All clones were
confirmed by DNA sequencing. The pSR659 or pSR661 constructs were co-transformed
with pDD866 into SU202 to perform heterodimerization assays. The pSR658 or pSR660
constructs were individually transformed into SU101 for homodimerization assays.
Expression of the LexA fusions were induced by IPTG and if the fusion proteins
interacted, a competent repressor was formed in the reporter strain that could bind the
operator site and decrease transcription of the lacZ reporter gene. This resulted in a
measurable decrease in β-galactosidase activity compared to a strain carrying the control
unfused vectors. However, because β-galactosidase is a long-lived enzyme, the reporter
strains were grown overnight in the presence of 1 mM IPTG so that any enzyme
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expressed prior to the LexA chimera induction is degraded. This strategy results in a more
reliable and accurate quantification of homodimerization and heterodimerization.
Following overnight incubation on LB agar plates with 1 mM IPTG and appropriate
antibiotics, reporter strains carrying the control vectors (pSR658 and pSR659 or pSR660
and pSR661) (75) or the LexA DBD fusions were inoculated and grown to an optical
density at 600 nm (OD600) of ~0.5 in LB broth with 1 mM IPTG and appropriate antibiotics.
Protein-protein interactions were quantified by β-galactosidase activity assays and
compared to the activity of the reporter strain carrying the unfused vectors, which has the
highest activity due to the lack of repressor formation. The algorithm for quantifying βgalactosidase activity was: [OD420-(1.75 x OD550)/(t x v x OD600)] x 1000, where t is time
of reaction development in minutes and v is volume of sample in milliliters (76). This
equation allows for the normalization of different culture densities for comparison
purposes.
Cloning and growth-recovery assays with VapC-1. To clone wild-type and
mutant VapC-1 genes for the growth-recovery assays, the wild-type vapC-1 gene was
amplified from NTHi strain 86-028NP genomic DNA, the vapC-1 D6N gene was amplified
from pDD757, the vapC-1 D99N gene was amplified from pDD758, the vapC-1 D6N D99N
gene was amplified from pDD1118, the vapC-1 E43Q gene was amplified from pDD1165,
the vapC-1 E43Q D99N gene was amplified from a synthetic gene produced by Eurofins,
and the vapC-1 E120Q gene was amplified from pDD1166 using high-fidelity Phusion
Flash DNA polymerase with pBAD86C1SacFor and 322Rev primers. The PCR products
and pBAD33 were digested with SacI and HindIII prior to ligation, resulting in pDD946,
pDD1132, pDD1133, pDD1119, pDD1175 pDD1194, and pDD1174. The forward primer
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was designed to include the putative Shine-Dalgarno sequence for VapC-1. The vapB-1
gene was amplified from 86-028NP genomic DNA using high-fidelity Phusion Flash DNA
Polymerase with 321LexFor and 321LexRev primers. After digestion with SacI and KpnI
the PCR fragment was ligated into pTrcHisA, resulting in pDD935. All clones were verified
by DNA sequencing. Wild-type vapC-1 and each of the six mutants were co-transformed
with pDD935 into E. coli strain LMG194.
To perform the growth-recovery assays, strains were grown at 37 °C to early log
phase (OD600 of ~0.2 - 0.3) in LB broth with 20 µg/mL chloramphenicol and 100 µg/mL
ampicillin before being diluted in a 1:1 (vol:vol) ratio to a final volume of 150 microliters of
media in a 96-well CorningTM FalconTM polystyrene microplate (Corning, Corning, NY,
USA) containing LB broth with 20 µg/mL chloramphenicol and 100 µg/mL ampicillin, with
or without 1 mM IPTG, 6.6 mM (0.1% wt/vol) arabinose, or both. The final induction
concentrations were 0.5 mM IPTG and 3.3 mM (0.05% wt/vol) arabinose. The plate was
covered with a gas permeable membrane, loaded into a Multiskan FC incubating plate
reader (Thermo Fisher Scientific, Waltham, MA USA), and incubated at 37 °C with a
shaking protocol of 5 s on and 5 s off with measurements taken every 10 min at OD595 for
190 min. Each assay included three biological replicates with three technical replicates.
Construction of the in cis delivery system and reconstituted NTHi strains.
Based on a previously published ectopic delivery vector in NTHi (106), the metE
pseudogene in the chromosome of strain 86-028NP (NTHI_RS09270) was targeted as
the site for gene delivery and single-copy expression in cis. The delivery vector was
constructed by amplifying 843 bp of the 5’ end of NTHI_RS09270 from 86-028NP
genomic DNA using high-fidelity Phusion Flash DNA polymerase with 2009-1SacFor and
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2009-1XbaRev primers and ligating the product into pBluescript SK+ digested with SacI
and XbaI, resulting in pDD1058. The second homologous region of 767 bp of the 3’ end
of NTHI_RS09270 was amplified from 86-028NP genomic DNA using high-fidelity
Phusion Flash DNA polymerase with 2009-2XhoFor and 2009-2KpnRev primers and
ligated into pDD1058 cut with XhoI and KpnI, resulting in pDD1063. The last step was
amplifying a erythromycin resistance cassette from pEJ18 (107) with PermCSpeFor and
ErmCSpeRev primers and ligating into pDD1063 cut with SpeI, resulting in the delivery
vector, pDD1140. The native vapBC-1 promoter from 86-028NP was cloned into the
multiple cloning site of the delivery vector using the primers BC1PromBamFor and
BC1PromNdeRev. The reverse primer contains an engineered NdeI site (CATATG) in
which the ATG of the restriction site (underlined) serves as the start codon for the fused
vapBC-1 genes. This allowed us to clone all constructs with their native transcriptional
regulation and organization. The vapBC-1 promoter was ligated to pDD1140 cut with
BamHI and EcoRV, resulting in pDD1155. Because the vapC-1 mutants are in tandem
with the wild-type vapB-1 gene, each was cloned into pDD1155 for delivery into the 86028NP chromosome. The vapBC-1 D6N locus was amplified from pDD757, vapBC-1
D99N was amplified from pDD758, vapBC-1 D6N D99N was amplified from pDD1118,
vapBC-1 E43Q was amplified from pDD1165, vapBC-1 E43Q D99N was amplified from
a synthetic gene produced by Eurofins, vapBC-1 E120Q was amplified from pDD1166,
and wild-type vapBC-1 was amplified from pDD686 using high-fidelity Phusion Flash DNA
polymerase with 86B1NdeFor and 322Rev primers. Each amplicon was ligated to
pDD1155 digested with NdeI and HindIII, resulting in pDD1159, pDD1160, pDD1161,
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pDD1167, pDD1204, pDD1168, and pDD1169. This resulted in vapBC-1 with the desired
mutations in vapC-1 under the control of its native promoter (Fig. 12).
The strains of NTHi 86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC1 with wild-type vapC-1 and the six mutants were constructed by homologous
recombination into the chromosome of 86-028NP ΔvapBC-1 by PCR products containing
both the flanking regions of NTHI_RS09270 and each promoter::tandem clone using MIV
transformation (81). After selection on chocolate agar with 5 µg/mL erythromycin, a single
colony of each transformant was passaged three times on antibiotic-containing plates.
DNA sequencing of PCR-amplified genomic DNA preparations confirmed each correct
strain.
To ensure the in cis fusions did not affect the growth dynamics of NTHi, strains
were grown to early log phase (OD600 of ~0.2 - 0.3) in sBHI broth before dilution into a
96-well CorningTM FalconTM polystyrene microplate, and absorbance was measured
following the same protocol as the growth-recovery assays over the course of 7 h. Each
growth assay included three biological replicates with three technical replicates.
NTHi infections of primary human tissues. EpiAirwayTM tissues (AIR-100-ABF,
MatTek, Ashland, MA USA) were maintained, inoculated, and harvested as previously
described (108) with the following exception: inserts were inoculated with approximately
25 µl 1.0 x 104 CFU/mL bacterial suspension of the desired strain. Inserts were cocultured
with the parent, wild-type or mutant strains for 48 h before harvesting and quantification
by counting viable colonies from a plated dilution series on chocolate agar plates.
Statistical analyses. Differences between means were determined using the
Student’s t-test. Differences among multiple-group treatments were determined by the
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repeated measures ANOVA or two-tailed ANOVA as appropriate using GraphPad Prism
8.0.1 (GraphPad Software, La Jolla, CA USA). A p value of <0.05 was considered
statistically significant.
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USE OF THE L-ARABINOSE-INDUCIBLE ESCHERICHIA COLI ARABAD
PROMOTER AND THE ARAC REGULATOR IN HAEMOPHILUS INFLUENZAE
INTRODUCTION
The discovery of inducible promoters to express genes has provided scientists with
valuable tools to study gene expression. There are a wide variety of promoters with
various regulators and induction methods available; however, the Ptrc (78), Plac (109-111),
Ptac (111-113), PT7 (114), and PBAD (77) promoters are among the more popular
expression systems. The PBAD expression vectors are extremely useful due to the tight
regulation of the promoter via the regulatory gene, araC, the fast induction rate, and the
ability to modulate the level of gene expression (77).
The arabinose system has been studied extensively in E. coli and is composed of
two independent transport systems (araE and araFGH), a set of metabolism genes known
as the araBAD operon, and the regulatory gene, araC. The product of araE is a lowaffinity membrane protein that uses the electrochemical potential to transport arabinose
into the cell (115, 116). The araFGH operon is a second high-affinity arabinose
transporter belonging to the ATP-binding cassette (ABC) transporter family (117, 118).
AraF is the arabinose-binding protein located in the periplasm (119), AraG binds ATP,
and AraH is a membrane-associated protein involved in arabinose transport into the cell
(117, 120). The araBAD operon converts L-arabinose to D-xylulose-phosphate, part of
the pentose phosphate pathway, for use by bacteria in central metabolism (121). AraC is
the regulatory protein of the arabinose system (122, 123). It positively regulates the
promoters of araBAD, araE, and araFGH in the presence of arabinose (124); it negatively
regulates the araBAD promoter in the absence of arabinose, and it negatively regulates
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its own promoter in the presence and absence of arabinose (125). Two mechanisms
describe the regulatory functions of the arabinose-specific AraC protein: DNA looping
(126, 127) and the light-switch mechanism (128, 129). In DNA looping, a protein or protein
complex binds to two different sites of DNA causing it to create a loop (130). This looping
decreases the concentration of the regulator, for example AraC, while still repressing
gene expression. Conversely, the light-switch mechanism facilitates positions and
orientations of the regulator protein(s) that favors DNA looping (131). When the regulator
protein is in one position, DNA looping occurs and when the interaction changes, the loop
can be broken to initiation transcription, simulating the on and off function of a light-switch.
AraC functions as a homodimer. Each monomer has two domains connected by a flexible
linker: a dimerization domain that binds arabinose and a DNA-binding domain (Fig. 14).
In the absence of arabinose, AraC binds to araO2 (O2) and araI (I1) causing the DNA to
bend, creating a loop (126, 127). Meanwhile, the N-terminal arm extends from the
arabinose-binding domain to the C-terminal DNA-binding domain, keeping the arabinose
binding site exposed for arabinose when it becomes available (132). When arabinose
arabinose is present, it sits in the arabinose-binding domain making it energetically
favorable for the N-terminal arms to fold over the pocket and bind to the dimerization
domains (129). When the arms release from the DNA-binding domains, it is energetically
favorable for AraC to bind to adjacent I1 and I2 half-sites, providing space for RNA
polymerase to bind to the PBAD promoter to initiate transcription (133, 134). The full
induction of the arabinose genes requires AraC as well as the catabolite activator protein
(CAP; also known as the cyclic AMP receptor protein) to bind upstream of the I1 and I2
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FIG 14 Regulation of the PBAD promoter by AraC. AraC is a homodimer. The C-terminal
DNA binding domains bind to the O2 and I1 sites when arabinose is not present. This
energetically favorable binding causes DNA to form a loop and inhibits RNA polymerase
from binding to the PBAD and PC promoters. The N-terminal dimerization domains have
arabinose-binding pockets. When arabinose binds, the N-terminal arm which was bound
to the DNA binding domain folds over the arabinose-binding domain in a process called
the light-switch mechanism. This facilitates a conformation change in the AraC
homodimer and the DNA-binding domain that was bound to the O2 site folds over to
bind to the I2 site. The DNA loop is released and RNA polymerase can now bind to the
PBAD and PC promoters to facilitate transcription. This image is reproduced from
reference 132 describing the history and mechanisms of AraC.
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operator sites (Fig. 14) and stimulate the transcription of the araBAD operon (77, 135).
Induction of the arabinose genes is inhibited by glucose levels because glucose reduces
levels of cAMP by inhibiting adenylate cyclase.
The expression system was originally designed for use in E. coli (77). However,
the need to achieve high levels of gene expression, particularly of toxic gene products,
has enticed scientists to expand the practical nature of the arabinose system into other
bacterial species. Scientists have utilized the PBAD promoter and the araC regulator for
routine cloning and gene expression to facilitate protein purification, analyze protein
function, and study complex cellular physiological properties in the following species:
Salmonella typhimurium (136), Agrobacterium tumefaciens (137), Corynebacterium
glutamicum (138), Xanthomonas campestris pv. phaseoli (139), Pseudomonas
aeruginosa (140), Vibrio cholerae (141), and Burkholderia cepacia (142).
Previous studies have found the PBAD expression vectors to be extremely useful to
study the ribonuclease toxin from type II TA loci. A growth recovery assay which utilized
the plasmid pBAD33 (77) allowed induction of gene expression by arabinose to evaluate
ribonuclease activity of VapC-1 mutants from NTHi in E. coli LMG194 (143).
While it is common to utilize E. coli to study genes expressed in other bacterial
species, in this study a novel assay was designed in the background of NTHi to test both
the transport of arabinose and the ability of this molecule to regulate the expression of TA
proteins in cis. Ideally, to study arabinose induction, a bacterial strain should be able to
transport but not degrade arabinose, so that the molecule remains available to induce the
PBAD promoter. An extensive BLAST search of NTHi genomes did not reveal genes that
were homologous to known arabinose transport proteins and catabolic enzymes (144). In
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this study, two novel NTHi delivery vectors were constructed: one that carried an araC
gene with a PBAD::vapD expression cassette, and another that delivers an arabinose
permease into the NTHi chromosome. Both genes were inducible by arabinose. These
were used to transform an NTHi strain with a deletion of the TA locus vapXD (R2866
ΔvapXD). Because the cassettes were flanked by DNA regions homologous to a target
site on the chromosome and included an antibiotic marker (Fig. 16 and 17), they were
recombined at the desired site following transformation and identification was facilitated
by antibiotic selection followed by DNA sequencing of the in cis cassette. Using this novel
design, the ability of the araC PBAD::vapD fusion to recombine into the NTHi chromosome
at the site of a naturally-occurring pseudogene was evaluated. Then, one of two E. coli
arabinose permease cassettes (comprised of either araE or araFGH) was targeted to
another non-utilized site on the chromosome, a partial bacteriophage terminase gene.
Upon successful homologous recombination of the toxin only, or the toxin with one of the
two arabinose permease cassettes, expression of the toxin VapD with or without an
arabinose permease was induced. Likewise, the ability of each permease to transport
arabinose when expressed in NTHi was compared. A bioassay was then designed to
measure the amount of arabinose uptake by NTHi by detecting the amount of arabinose
left in the media after NTHi growth (hereinafter called conditioned media). This bioassay
uses the expression of a green fluorescent protein (GFP) gene under the control of the
PBAD promoter from the plasmid pGLO (Bio-Rad, Hercules, CA) in E. coli strain LMG194
which is inducible by arabinose. First, it was demonstrated that arabinose could modulate
GFP expression in chemically defined media using a dose-response control curve.
Subsequently, this bioassay was used to measure the arabinose remaining in conditioned
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media following NTHi growth at mid-log phase and also at stationary phase to determine
whether 1) NTHi could transport arabinose across its membrane, and 2) whether the
addition of either E. coli arabinose permease affected arabinose transport in NTHi.
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RESULTS
Growth dynamics of R2866 and the ΔvapXD mutant strain. To induce the
expression of the toxin VapD and antitoxin VapX in the background of NTHi, it was
necessary to create a vapXD deletion mutant to prevent crosstalk. The entire vapXD
operon was deleted in R2866 by replacing the locus with a chloramphenicol resistance
cassette. Following confirmation of deletion by PCR characterization of genomic DNA
using various flanking primers, growth curves were performed to determine if the deletion
had an effect on replication compared to the parent strain. No significant difference in the
growth dynamics between the two strains was observed in sBHI (Fig. 15) and in glucose
free DM with 10mM sodium pyruvate (data not shown).
Construction of two in cis ectopic systems to study type II TA protein
induction and arabinose permease function in NTHi. Use of a growth-recovery assay
in the background of E. coli LMG194 to study the activity of NTHi VapC-1 mutants under
the control of the PBAD promoter in trans was previously reported (143). While this is an
excellent tool, this study sought to create an assay in the background of NTHi to study
the function of the TA toxin VapD in cis to mimic the single copy toxin gene in the
chromosome. In addition, this study also sought to investigate whether the addition of an
E. coli arabinose permease in cis would increase arabinose transport across the NTHi
membrane.
To evaluate these aspects, two novel systems were developed. The first contained
both the arabinose operon regulatory gene, araC and the PBAD promoter controlling the
type II toxin, vapD (Fig. 16). This system mimicked the normal copy number of the gene
and placed it under the control of the artificially-inducible promoter PBAD. This module was
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FIG 15 Growth dynamic comparisons between R2866 and ΔvapXD deletion mutant
strains in sBHI. Strains were grown in a 96-well plate at 35°C with shaking. Data are
expressed as the mean + SD of three biological replicates in triplicate. No significant
difference was found between the growth of the parent strain, R2866 and the ΔvapXD
deletion mutant using the repeated-measures ANOVA.

54

FIG 16 R2866_RS09695 delivery vector for single-copy in cis expression of cloned
genes. (A) The construct targets the metH pseudogene in strain R2866; (B) contains
thearaC gene with the PBAD promoter fused to vapD.

FIG 17 R2866_RS04985 delivery vector for single-copy in cis expression of cloned
genes. (A) This construct targets the large subunit of the PBSX phage terminase gene
in strain R2866; (B) contains the araE gene; (C) contains the araFGH operon cloned
into pDD1230 under the control of their own promoters and are induced by arabinose.
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flanked by homologous regions of the metH pseudogene from the NTHi strain R2866
(R2866_RS09695), which targets the araC PBAD::vapD cassette to a chromosomal
region that is not in use. Briefly, cassettes were amplified by PCR, used to transform
NTHi, and were homologously recombined into the chromosome at the
R2866_RS09695 pseudogene site in single copy. An R2866 ΔvapXD deletion strain
was constructed as the background to analyze vapD induction to eliminate contributions
by the wild-type vapXD locus. The second cassette targeted either the low-affinity
arabinose permease gene, araE, or the high-affinity arabinose operon, araFGH into the
large subunit of the PBSX phage terminase gene (R2866_RS04985) (Fig. 17), which
was another region not utilized in NTHi. This novel approach resulted in a more
biologically relevant system to study the induction of type II ribonuclease toxins under
the control of the artificially-inducible PBAD promoter and to determine whether the
addition of an E. coli arabinose permease increased arabinose transport in the
background of NTHi.
NTHi growth recovery assay. Traditionally, the toxin proteins of TA modules
induce varying levels of growth arrest, whereas the antitoxins usually do not. Therefore,
the NTHi-based growth recovery assay was designed with the toxin in single copy in cis
and the antitoxin in multicopy in trans. The antitoxin, vapX, was evaluated in trans under
the control of the Ptrc promoter and its expression was induced with 1 mM IPTG (isopropylβ-ᴅ-thiogalactopyranoside) (145, 146). The toxin, vapD, was evaluated in cis under the
control of the PBAD promoter and was induced with 2.64 mM (0.04% wt/vol) arabinose
(77) with or without either the low-affinity arabinose permease, araE, or the high-affinity
arabinose permease, araFGH in cis (Fig. 18A to C). Thus, VapX and VapD could be
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induced either independently or simultaneously while also comparing the effectiveness of
an arabinose permease.
To initiate the assay, a culture in early growth phase was split and treated with
either: (i) media only, (ii) arabinose only, (iii) IPTG only, or (iv) both arabinose and IPTG.
The results of the experiments with vapD in cis with or without either arabinose permease
in cis induced with arabinose and vapX in trans induced with IPTG are presented in Fig.
18A to C. VapD, from NTHi strain 86-028NP, is a ribonuclease toxin (36), and was
induced in single copy in the background of NTHi to measure growth arrest. No significant
growth arrest was observed when vapD in cis was induced in vivo with or without the
addition of araE or araFGH (Fig. 18A to 18C, red symbols).
Modulation of expression of GFP in glucose-free defined media. One of the
advantages of using the PBAD promoter is the ability to modulate gene expression by
varying the arabinose concentration in the media (77). In that context, it is believed that
this is the first time an arabinose uptake and utilization system in NTHi defined media has
been tested (147). The pGLO (pBAD-GFPuv (148)) plasmid was utilized because the
reporter gene, GFP, is under the control of the PBAD promoter and therefore is inducible
by arabinose. Arabinose in dose-response concentrations was used to induced pGLO in
E. coli LMG194, using glucose-free defined media with 10 mM sodium pyruvate. Glucosefree media was used because glucose reduces levels of cAMP by inhibiting adenylate
cyclase which reduces CAP and therefore reduces induction of the arabinose genes as
previously described in the introduction. Therefore, using glucose-free media
supplemented with sodium pyruvate can increase the transcription of the araBAD operon
while still providing NTHi with a suitable carbon source. Relative fluorescence units per
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cell (RFU/cell) was calculated from GFP expression measured for each concentration of
arabinose (Fig. 19). This experiment shows that arabinose in glucose-free defined media
with 10 mM sodium pyruvate can modulate the expression of pGLO in LMG194 (Fig. 19).
All treatments were compared and found to be statistically significant using one-way
ANOVA.
Transport of arabinose in NTHi. Since the level of expression of GFP from the
plasmid pGLO induced in E. coli LMG194 reflected the amount of arabinose in the media
(Fig. 19), this characteristic was used as a bioassay to determine the concentration of
arabinose left in conditioned media after NTHi growth. The control was defined media
with arabinose that was treated identically to the conditioned media, but without NTHi. If
the amount of arabinose left in the conditioned media resembled the control media without
bacteria, then it would indicate NTHi did not transport arabinose into the cell. Likewise, if
the amount of arabinose left in the conditioned media was lower than in the control media
without cells, then it would suggest NTHi could transport arabinose from the media into
the cell. Finally, if the amount of arabinose left in the conditioned media from the strains
with one of the arabinose permeases in cis was lower than in the conditioned media from
strains with vapD only, then it could be due to increased arabinose transport by the
permease.
Conditioned media was obtained by inducing the following strains with 2.64 mM
(0.04% wt/vol) arabinose: R2866 ΔvapXD RS09695::araC PBAD::vapD, R2866 ΔvapXD
RS09695::araC PBAD::vapD RS04985::ParaE::araE, and R2866 ΔvapXD RS09695::araC
PBAD::vapD RS04985::ParaFGH::araFGH and growing each to mid-log phase (approximate
OD600 of 0.4) and to stationary phase (approximate OD600 of 1.3). Two growth phases
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were chosen to determine if arabinose transport was affected by metabolism and/or cell
growth in NTHi. The control was media treated with 2.64 mM (0.04% wt/vol) arabinose
with no bacteria. The RFU/cell for the control and for each sample of conditioned media
was calculated. The RFU/cell of the control was not significantly different from the
conditioned media collected during mid-log or stationary phase for all three strains
determined by the one-way ANOVA (Fig. 20). This result indicates that 1) arabinose
cannot cross the membrane of NTHi, and 2) that the addition of the arabinose permease
gene, araE, or the arabinose permease operon, araFGH from E. coli were not
advantageous to arabinose transport in NTHi.
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FIG 18 NTHi growth recovery assays in glucose-free defined media with 10 mM sodium
pyruvate. NTHi growth-recovery assays with inducible VapX in trans and VapD in cis.
(A) Without an arabinose permease; (B) with araE in cis; (C) with araFGH in cis. Noninduced NTHi growth (measured by absorbance at 595 nm) or growth following
induction of VapD, VapX, or both VapD and VapX. All data are plotted as the mean ±
SD of three biological replicates in triplicate. There was no statistical significance among
the four treatment groups using repeated-measures ANOVA.
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FIG 19 Modulation of GFP expression from the plasmid pGLO in E.coli LMG194. pGLO
in E. coli LMG194 was treated with arabinose in four 10-fold dilutions or without
arabinose. The relative fluorescence unit (RFU) per cell was calculated by dividing the
total RFU by the number of cells (determined by the final OD595) per arabinose
treatment group. The fluorescence of the negative control (media alone) was subtracted
from each value. Data are expressed as the mean + SD of two biological replicates in
quadruplicate. Statistical comparisons were made among all treatment groups and all
samples were significantly different (P < 0.05) from each other using one-way ANOVA.
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FIG 20 Transport of arabinose in NTHi. The amount of arabinose left in conditioned
media was measured after growing NTHi strains with and without an additional
arabinose permease to (A) mid-log phase (approximate OD600 of 0.4) or (B) stationary
phase (approximate OD600 of 1.3) to measure if arabinose transport was affected by
metabolism and/or cell growth. The cells were pelleted and the medium passed through
a 0.2 micron filter. The control was media treated identically to the conditioned media,
but without NTHi. The conditioned media and the control were used to induce pGLO in
E. coli LMG194 to compare the amount of arabinose remaining in the conditioned media
to the control media. RFU per cell was calculated by dividing the total RFU by the
number of cells (determined by the final OD595) for each strain. The fluorescence of the
negative control (media alone) was subtracted from each value. Data are expressed as
the mean + SD of two biological replicates in quadruplicate of each strain of conditioned
media. Statistical comparisons were made between the results of the conditioned media
and the control and were not significantly different by one-way ANOVA.
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DISCUSSION
The use of the PBAD promoter with the regulatory functions of AraC is an efficient
and highly useful way to study gene expression in a number of different bacterial strains.
Expanding its use to organisms that live in niche environments, such as NTHi, provides
another tool to study genes that aid bacteria in causing infections in human hosts and
evading the immune response. A good example is the type II TA systems, which have
been shown to be crucial for the survival of NTHi during infection, both ex vivo in primary
human tissues and in vivo in the chinchilla model of acute otitis media (36, 60).
Other studies have successfully evaluated the use of the Ptrc (146) and the PxylA
(149) in NTHi. The Ptrc promoter is induced by IPTG, a synthetic molecule similar to
allolactose, but is not hydrolyzed by β-galactosidase. Because IPTG is not degraded,
concentrations remain constant during experiments. Use of the PxylA promoter is a novel
idea because, like the PBAD promoter, its tight regulation is particularly important for the
study of essential or toxic genes. However, this promoter is induced by xylose, a fivecarbon sugar catabolized by many species, so it is important to verify catabolism genes
in a species before utilizing this system. A number of studies have used the P xyl from the
particular species they are investigating and unlike promoters that are induced by IPTG
and arabinose, there are no commercially-available plasmids that utilize Pxyl for gene
expression.
In this study, araC with PBAD::vapD was transformed into the chromosome of NTHi
via homologous recombination at the site of a pseudogene. Two different arabinose
permeases were also transformed into NTHi via homologous recombination at a
bacteriophage terminase site to determine if an E. coli arabinose permease increased
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arabinose transport across the membrane. Even when an arabinose permease was
present, no significant amount of growth arrest upon induction of vapD in cis was
observed (Fig. 18). It has been previously shown that the TA toxins VapC-1, VapD, and
ToxA have ribonuclease activity (36, 46, 60, 85). It has also been shown that their
corresponding TA operons contribute to survival of NTHi during infection (36, 60).
However, it is important to note that the timeline of the assays utilized to measure effects
on survival were over a period of 2-4 days. The first model, the EpiAirways (AIR 100 ABF;
MatTek, Ashland, MA, USA), consists of primary human respiratory epithelial tissue at
the air-liquid interface infected by NTHi over two (or more) days and is the closest in vitro
model of the human upper airway that is currently available (108). In the second model,
the chinchilla model of experimental otitis media, NTHi infection is quantified over four
days and is extremely useful in the study of this and other auditory and respiratory tract
infections due to the anatomical and physiological similarities between the chinchilla
middle ear and that of humans (150). Through fluorescence measurements of pGLO in
E. coli LMG194, the equal concentrations of arabinose in conditioned media compared to
the arabinose-only control demonstrated that arabinose did not cross the NTHi membrane
even with the addition of an E. coli arabinose permease (Fig. 20). It may be useful to
explore araC with PBAD::vapD and permease induction with arabinose on a plasmid in
trans in the background of NTHi. However, it would difficult to induce the antitoxin, toxin,
and a permease in trans because all three plasmids would need to be compatible in the
background of NTHi. This is a challenging task due to the diversity of the NTHi genome
(151). H. influenzae strains are naturally competent and can transport several hundred
kilobases of foreign DNA fragments at a time from the environment (152, 153). The
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advantages of DNA uptake include using the nucleotides as a food source, repair of
damaged DNA, and recombination into the chromosome to acquire new genes that may
be beneficial to cellular survival. The latter has implications in plasmid maintenance
because new DNA that has homologously recombined into the chromosome of H.
influenzae could be antibiotic resistance genes, new virulence factors, or origins of
replication that may affect plasmid replication. A large challenge faced while conducting
experiments with NTHi has been differences in plasmid survivability between two NTHi
strains, namely 86-028NP and R2866. In fact, it was not possible to construct the araC
with PBAD::vapD recombinant at the targeted pseudogene site in 86-028NP. For reasons
currently unknown, the 86-028NP strain generated only spontaneous mutants rather than
recombinants (data not shown).
H. influenzae survives as a commensal in a niche environment, the upper
respiratory tract of the human host, a unique setting. It can also act as a pathogen in the
middle ear, nasopharynx, and lung (154). Finally, it can invade the bloodstream and the
cerebrospinal fluid (CSF) as well (155). These areas differ greatly in nutrient and oxygen
availability (156). For example, mucous membranes, biofilms, and the middle ear have
limited oxygen levels (157) compared to epithelial surfaces (158). Serum-resistant
invasive strains can disrupt epithelial cells and penetrate into the bloodstream and
ultimately cause infection of the CSF. However, the CSF is 99% water, which limits
nutrients for H. influenzae (159), and has lower oxygen tension compared to that of the
bloodstream. Therefore, it is necessary for NTHi to maintain genes that help it quickly
adapt to these changes in its microenvironment (160).
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A study of metabolic diversity in H. influenzae determined that all species
maintained enzymes for the Embden-Meyerhof-Parnas (EMP) pathway (with the
exception of glucokinase), and all the enzymes in the pentose phosphate pathway for
glucose degradation (PPP) (161). As a follow-on, researchers investigated the metabolic
and physiological properties of four strains: one respiratory tract isolate (Hi2019), two
invasive strains (R2866 and C188), and the reference strain (Rd KW20) (156, 161, 162).
However, even though the central carbon metabolic pathway is highly conserved among
strains, pathway preference and carbon source utilization differed (156, 161). While
interesting, this result is not unexpected; NTHi must quickly adapt to changes in the host
in order to survive. Researchers have shown that NTHi has transport capabilities for
glucose, xylose, ribose, galactose, fructose, glycerol, fucose, pyruvate, and sialic acid
(152, 163, 164). Although NTHi has the ability to transport and catabolize a range of
carbon sources, no reports mention arabinose availability in areas NTHi colonizes. NTHi
does not maintain homologues to the arabinose transport and catabolism genes;
however, it may be possible for another pathway to transport arabinose. While the
bioassay to determine arabinose transport provided evidence that R2866 did not transport
arabinose (Fig. 20), further investigation into arabinose transport and catabolism in other
strains of NTHi might be valuable, as the use of the arabinose-inducible PBAD vectors
would be extremely useful tools in the study of gene expression.
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MATERIALS AND METHODS
Bacterial strains and culture conditions. The bacterial strains and plasmids
used in these studies are listed in Table 6. E. coli strains were grown in LB broth or agar
with or without 100 µg/mL ampicillin, 250 µg/ mL erythromycin, 20 µg/mL
chloramphenicol, 100 µg/mL spectinomycin, or 10 µg/mL gentamicin, as required. E. coli
strains were routinely cultured for 18 h at 37 °C. NTHi strains were grown in brain heart
infusion broth or agar supplemented with 10 μg/mL heme-histidine and 10 μg/mL β-NAD
(sBHI), chocolate agar with 5 U/mL bacitracin, or defined media (147) with or without
glucose supplemented with 10 mM sodium pyruvate. NTHi were routinely cultured for 18
h at 37 °C with 5% CO2. To construct the ectopic strains, recombinants were selected on
chocolate agar plates with 2 μg/mL chloramphenicol, 25 μg/mL spectinomycin, or 5 μg/mL
erythromycin. Single colonies were passaged for 3 days on selection plates before being
confirmed by DNA sequencing of PCR-amplified purified genomic DNA.
Construction of an NTHi strain R2866 ΔvapXD mutant. The vapXD operon was
previously deleted from NTHi strain 86-028NP (36). Due to the sequence homology
between strains 86-028NP and R2866 flanking the vapXD operon (165), a PCR product
from pDD788 (36) and the MIV transformation protocol (81) were used to create the
R2866 ΔvapXD deletion mutant. Recombinants were selected on chocolate agar plates
with chloramphenicol for three days. Genomic DNA preparations were used to
characterize the deletion via PCR using primers that flanked the deletion.
To compare the growth dynamics, the parent and mutant strains were resuspended from sBHI plates into fresh sBHI broth. The strains were grown to early log
phase (OD600 of ~0.2 - 0.3) before being diluted into a 1:1 (vol:vol) ratio to a final volume
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TABLE 5 Bacteria, plasmids and primers used in this study
Strains

Description

Source

DH5α

F– Φ80lacZΔM15 Δ(lacZYA-argF)
U169 recA1 endA1 hsdR17 (rK–,
mK+) phoA supE44 λ– thi-1 gyrA96 relA1

Laboratory
collection

LMG194

F- ΔlacX74 galE thi rpsL ΔphoA (PvuII) Δara714
leu::Tn10

Invitrogen

DD12

MC4100 recA::RP4-2-Tc::Mu, kanamycin
resistance

(146)

R2866

Blood isolate from an immunocompetent child with
meningitis immunized with the Hib vaccine

A.L. Smith

R2866 ΔvapXD

vapXD TA locus replaced with a chloramphenicol
resistance cassette

This work

R2866 ΔvapXD
RS09695::araC PBAD::vapD

R2866 ΔvapXD with araC with PBAD::vapD in cis

This work

R2866 ΔvapXD
RS09695::araC PBAD::vapD
RS04985::ParaE::araE

R2866 ΔvapXD with araC with PBAD::vapD and
ParaE::araE in cis

This work

R2866 ΔvapXD
RS09695::araC PBAD::vapD
RS04985::ParaFGH::araFGH

R2866 ΔvapXD with araC with PBAD::vapD and
ParaE::araFGH in cis

This work

R2866 ΔvapXD
RS09695::araC PBAD::vapD
+ (pDD1233)

R2866 ΔvapXD with araC with PBAD::vapD in cis
and lacIq with Ptrc::vapX in trans

This work

R2866 ΔvapXD
RS09695::araC PBAD::vapD
RS04985::ParaE::araE
+ (pDD1233)
R2866 ΔvapXD
RS09695::araC PBAD::vapD
RS04985::ParaFGH::araFGH
+ (pDD1233)

R2866 ΔvapXD with araC with PBAD::vapD and
ParaE::araE in cis and lacIq with Ptrc::vapX in trans

This work

R2866 ΔvapXD with araC with PBAD::vapD and
ParaE::araFGH in cis and lacIq with Ptrc::vapX in
trans

This work

Plasmids

Description

Source

pBAD33

Highly regulated expression vector,
chloramphenicol resistant

(77)

pTrcHis2A

Expression vector with C-terminal polyhistidine tag,
ampicillin resistant

Invitrogen

pBluescript SK(+)

Cloning vector, ampicillin resistant

Laboratory
Collection
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TABLE 5 Continued
Plasmids

Description

Source

pSPEC1

Source of spectinomycin resistance cassette

(166)

pEJ18

Source of erythromycin resistance cassette

(107)

pGLO

pBAD-GFPuv, ampicillin resistant

Bio-Rad

pDD514

RSF1010 ori broad host range vector, gentamicin
resistant

(146)

pDD788

pBluescript SK(+) with the vapXD deletion

(36)

pDD1020

5’ end of R2866_RS09695 in pBluescript SK(+)

This work

pDD1021

3’ end R2866_RS09695 in pDD1020

This work

pDD1022

R2866_RS09695 spectinomycin resistant -targeted
delivery vector

This work

pDD1077

vapX in pTrcHis2A

This work

pDD1218

vapD in pBAD33

This work

pDD1227

pDD1022 with araC with PBAD::vapD

This work

pDD1228

5’ end of R2866_RS04985 in pBluescript SK(+)

This work

pDD1229

3’ end R2866_RS04985 in pDD1229

This work

pDD1230

NTHI_RS04985 erythromycin resistant - targeted
delivery vector

This work

pDD1233

lacIq with Ptrc::vapX in pDD514

This work

pDD1235

pDD1230 with araE

This work

pDD1236

pDD1230 with araFGH

This work

Primers

Description

Source

PvapDXba+SDFor

AAAATCTAGAATAAGGAAAATTATGTACG

Eurofins

pBAD33VapDHindRev

TAGGAAGCTTTTAATTTCGTATAAAATCAG

Eurofins

VapXSKSacFor

AAAAGAGCTCTATGGAACTAAGACAAC

Eurofins

86VapLexRev (KpnI)

ATAAGGTACCTTATTCAGCTTCGG

Eurofins

Xlacl for (XbaI)

GTCATCTAGAAAACGCGCGAGGCAGC

IDT

Xhis rev (XbaI)

TATTTGTCTAGAGGCAGTTCCCTACTCTCG

IDT

1356-1SacFor

AAAAGAGCTCAACTTAAACAAGCTC

Eurofins

1356-1SpeRev

AATTACTAGTAGCCTCTTCAATAC

Eurofins
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TABLE 5 Continued
Primers

Description

Source

1356-2XhoFor

TTTCCTCGAGTTTAGCGGTGAATGG

Eurofins

1356-2KpnRev

AAAAGGTACCACACCCAACCACTTC

Eurofins

SpecPstFor

ACAACTGCAGAGATCTATCGATTTTCG

Eurofins

SpecPstRev

AAGCCTGCAGAGATCTGTACATCG

Eurofins

pBAD33BgIIIRev

TTATAGATCTTATTGTCTCATGAG

Eurofins

pBAD33BgIIIFor

TATCAGATCTGCATAATGTGC

Eurofins

RS04985-1SacFor

ATTTGAGCTCAAATTCCGACCGCTC

Eurofins

RS04985-1XbaRev

AGTATCTAGACCAAGTTTGAGATGC

Eurofins

RS04985-2XhoFor

AAGGCTCGAGTTGATGTGGCAGATG

Eurofins

RS04985-2KpnRev

AAAAGGTACCGGCGTAGCACATAAC

Eurofins

PermCSpeFor

AAATACTAGTAACACACACGCCATTCC

Eurofins

ErmCSpeRev

GTTAACTAGTGCAGTTATGCATCC

Eurofins

ParaESpeFor

GATGACTAGTATAGTGTTCCTTGCC

Eurofins

AraESpeStopRev

TTAAACTAGTTCAGACGCCGATATTT

Eurofins

ParaFGHSpeFor

AGGCACTAGTTATGGATTAATCTGC

Eurofins

AraFGHSpeRev

AAAAACTAGTTCAGACAGTGCGTTTCG

Eurofins
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of 150 microliters of media in a 96-well Falcon polystyrene microplate (Corning, Corning,
NY). The plate was covered with a gas permeable membrane, loaded into a Multiskan
FC incubating plate reader (Thermo Fisher Scientific, Waltham, MA USA), and incubated
at 35°C with a shaking protocol of five seconds on, five seconds off with measurements
taken every 10 mins at OD595 for 7 h. Each growth assay included three biological
replicates with three technical replicates.
Construction of artificially-inducible NTHi genes in E. coli. To transform this
system into NTHi, the toxin, vapD, was cloned into plasmid pBAD33 so that it was under
control of an arabinose-inducible promoter. NTHi strain 86-028NP genomic DNA was
used to amplify vapD with PvapDXba+SDFor and pBAD33VapDHindRev primers. After
digestion with XbaI and HindIII, the PCR fragment was ligated to pBAD33, resulting in
pDD1218 (vapD under the control of the PBAD promoter). VapXSKSacFor and
86VapLexRev primers were used to amplify vapX from 86-028NP genomic DNA. The
PCR fragment was digested with SacI and KpnI and ligated to pTrcHis2A, resulting in
pDD1077 (vapX under the control of the Ptrc promoter). XlacIFor and XhisRev primers
were used to amplify pDD1077. This PCR product was digested with XbaI and ligated to
the broad-host range conjugal vector, pDD514 (146), resulting in pDD1233.
Construction of the in cis delivery systems and reconstituted NTHi strains.
Based on previously published ectopic delivery vectors in NTHi (106, 143), two locations
in the genome of R2866 were targeted for gene delivery. The metH pseudogene
(R2866_RS09695) and the large subunit of the PBSX phage terminase gene
(R2866_RS04985) were chosen as sites for gene delivery in cis. The large subunit of the
PBSX phage terminase gene was chosen because R2866 only maintains a portion of the
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PBSX bacteriophage genome. After scrutiny of the R2866 genome, it was determined
that this gene would provide enough flanking regions to enable the homologous
recombination of a large PCR product into the genome without impeding vital genes
necessary for bacterial metabolism and replication.
The R2866_RS09695 targeted delivery vector was constructed by amplifying 899
bp of the 5’ end of R2866_RS09695 from R2866 genomic DNA with 1356-1SacFor and
1356-1SpeRev primers and ligating the product into pBluescript SK(+) digested with SacI
and XbaI (produces a compatible overhang which can be ligated to SpeI), resulting in
pDD1020. The second homologous region of 953 bp of the 3’ end of R2866_RS09695
was amplified from R2866 genomic DNA with 1356-2XhoFor and 1356-2KpnRev primers
and ligated into pDD1020 digested with XhoI and KpnI, resulting in pDD1021. The last
step was amplifying a spectinomycin resistance cassette from pSPEC1 (166) with
SpecPstFor and SpecPstRev primers and ligating to pDD1021 digested with PstI,
resulting in the delivery vector, pDD1022 (Fig. 16A). The primers pBAD33BgIIIFor and
pBAD33BgIIIRev were used to amplify pDD1218. The PCR product was digested with
BglII and ligated into pDD1022 digested with BamHI (produces a compatible overhang
which can be ligated to BgIII), resulting in pDD1227 (Fig. 16B). This arabinose-inducible
targeted delivery vector resulted in the fusion of araC to the PBAD promoter controlling
vapD.
R2866 ΔvapXD was made chemically competent (81) and the R2866 ΔvapXD
RS09695::araC with PBAD::vapD mutant was constructed by homologous recombination
of the PCR product using pDD1227 template. After selection on chocolate agar with 25
µg/mL spectinomycin, a single colony of each transformant was passaged three times on
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antibiotic-containing plates. DNA sequencing of PCR-amplified genomic DNA
preparations confirmed the correct strain.
The R2866_RS04985 delivery vector was constructed by amplifying 697 bp of the
5’ end of R2866_RS04985 from R2866 genomic with RS04985-1SacFor and RS049851XbaRev primers and ligating the product into pBluescript SK(+) digested with SacI and
XbaI, resulting in pDD1228. The second homologous region of 592 bp of the 3’ end of
R2866_RS04985 was amplified from R2866 genomic DNA with RS04985-2XhoFor and
RS04985-2KpnRev primers and ligated into pDD1228 digested with XhoI and KpnI,
resulting in pDD1229. The last step was amplifying an erythromycin resistance cassette
from pEJ18 (107) with PermCSpeFor and ErmCSpeRev primers and ligating into
pDD1229 digested with SpeI, resulting in the second delivery vector, pDD1230 (Fig. 17A).
Two different arabinose permeases were amplified from E. coli strain DH5α
genomic DNA to individually clone into pDD1230. The first permease, the low-affinity
arabinose transporter, araE, was amplified with ParaESpeFor and AraESpeStopRev
primers. The second permease, the high-affinity arabinose transporter, araFGH, was
amplified with ParaFGHSpeFor and AraFGHSpeRev primers. Both products were
digested with SpeI and ligated into pDD1230, resulting in pDD1235 and pDD1236,
respectfully (Fig. 17B and C).
R2866 ΔvapXD R2866_RS09695::araC with PBAD::vapD was made chemically
competent (81) to independently transform pDD1235 and pDD1236 into the chromosome,
resulting

in

R2866

ΔvapXD

R2866_RS09695::araC

with

PBAD::vapD

RS04985::ParaE::araE and R2866 ΔvapXD R2866_RS09695::araC with PBAD::vapD
RS04985::ParaFGH::araFGH. After selection on chocolate agar with 5 µg/mL erythromycin,
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a single colony of each transformant was passaged three times on antibiotic-containing
plates. PCR-characterized genomic DNA preparations confirmed each correct strain.
Construction of the in trans delivery systems into reconstituted NTHi strains.
The antitoxin, VapX, was cloned into pDD1233 as previously mentioned. To induce VapD
and VapX independently in the same strain, it was necessary to utilize two different
promoters with different inducers. Due to the small, finely tuned genome size of many
NTHi strains, it is particularly difficult to find unnecessary areas of the genome to utilize
for targeted delivery systems. For this reason, the antitoxin in pDD1233 was conjugated
into the newly constructed strains R2866 ΔvapXD R2866_RS09695::araC with
PBAD::vapD,

R2866

ΔvapXD

R2866_RS09695::araC

with

PBAD::vapD

RS04985::ParaE::araE, and R2866 ΔvapXD R2866_RS09695::araC with PBAD::vapD
RS04985::ParaFGH::araFGH (146). After selection on chocolate agar with 5 µg/mL
gentamicin, transconjugates were passaged three times on antibiotic-containing plates.
PCR-characterized plasmid preparations confirmed that pDD1233 was successfully
transferred to each strain.
Modulation of expression of GFP in glucose-free defined media. The plasmid
pGLO in E. coli LMG194 was used to measure the expression of GFP. The LMG194
strain with pGLO was re-suspended from glucose-free defined media with 10 mM sodium
pyruvate agar and 100 µg/mL ampicillin into identical broth media without agar to an
approximate OD600 of 0.16. The re-suspended culture was diluted into a 1:1 (vol:vol) ratio
to a final volume of 150 microliters of medium in a 96-well Falcon polystyrene microplate
(Corning, Corning, NY) containing identical media with 100 µg/mL ampicillin and 26.4 mM
(0.4% wt/vol) arabinose in four 10-fold dilutions down to 0.0264 mM (0.0004% wt/vol) or
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media without arabinose. The final induction concentrations were 13.2 (0.2% wt/vol), 1.32
mM (0.02% wt/vol), 0.132 mM (0.002% wt/vol), and 0.0132 mM (0.0002% wt/vol)
arabinose. The plate was covered with a gas permeable membrane, loaded into a
Multiskan FC incubating plate reader (Thermo Fisher Scientific, Waltham, MA USA), and
incubated at 35 °C with a shaking protocol of five seconds on, five seconds off for 12 h.
The final OD595 was recorded and florescence intensity was measured (405 nm excitation,
520 nm emission) on a FLUOstar OPTIMA Microplate Reader (BMG LABTECH,
Ortenberg, Germany). For E. coli, each 0.1 OD unit of absorbance equals approximately
1.0 x 108 cells/mL (167). Using the final OD595, the number of cells per treatment group
were calculated to determine the RFU/cell. Each assay included two biological and four
technical replicates.
Measuring the transport of arabinose in NTHi. The strains were re-suspended
from glucose-free defined media with 10 mM sodium pyruvate agar plates into identical
fresh media without agar at an initial OD600 of 0.1. They were immediately induced with
2.65 mM (0.04% wt/vol) arabinose and grown to mid-log phase (approximate OD600 of
0.4) or stationary phase (approximate OD600 of 1.3). When the final OD600 was reached,
aliquots were centrifuged at 13,000 x g for 10 min to pellet cells and cell debris. The
supernatant was filter-sterilized through a 0.2 micron polyethersulfone membrane. The
control was treated identically to the conditioned media except it was not inoculated with
NTHi. The sterilized supernatants (conditioned media and NTHi-free media control) were
used in the pGLO in LMG194 fluorescence assays to determine if there was a difference
in arabinose concentrations remaining in the conditioned media versus the control.
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pGLO in LMG194 was re-suspended from glucose-free defined media with 10 mM
sodium pyruvate agar and 100 µg/mL ampicillin into identical media without agar to
approximately OD600 0.16. The re-suspended culture was diluted into a 1:1 (vol:vol) ratio
to a final volume of 150 microliters of media in a 96-well microplate with the conditioned
media and control. The same protocol described in the pGLO fluorescence experiment
was used to measure GFP fluorescence induced by the conditioned media and control.
Each assay included three biological and four technical replicates.
Statistical analyses. Differences among multiple-group treatments were
determined by the one-way or the repeated-measures ANOVA as appropriate using
GraphPad Prism 8.1.2 (GraphPad Software, La Jolla, CA USA). A P value of <0.05 was
considered statistically significant.
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ANALYSIS OF THE GENOME ORGANIZATION OF FOUR TA LOCI IN 12 CLINICAL
ISOLATES OF NONTYPEABLE HAEMOPHILUS INFLUENZAE
INTRODUCTION
In 1995, H. influenzae was the first free-living organism to have its genome
sequenced (168). This sparked the “genome era” and since then, 204,683 partial and
whole bacterial sequences, 735 being Haemophilus influenzae strains, have been
deposited into Genbank (169). As the community shifts from Sanger sequencing to nextgeneration sequencing (NGS), it has become much more feasible for clinicians and
researchers to quickly and accurately sequence the genomes of bacterial isolates inhouse and analyze the data (170). These higher-throughput methods are useful for
tracking epidemiological data and targeting current or potential outbreaks. NGS can also
be a beneficial way to customize treatment plans by sequencing the causative agent(s)
of major bacterial infections and tailoring antimicrobial therapy based on the resistance
genes present in the isolates involved in the infection. Targeted therapy is predicted to
become an increasing focus because unintended consequences of antibiotic use can
alter the microbiome, activate toxin-antitoxin systems, establish of environmental
reservoirs, and increase the speed in which bacteria develop resistance to current drugs
(145). A list of FDA-approved antibiotics and their approval years was recently reported
(145). There was an increase in approval of new antibiotics from the late-1930’s until the
mid-1980’s (Fig. 21). After that time, there was a steady decline in FDA-approved
antibiotics. The increase in antibiotic resistance and decreased support for antibiotic drug
discovery has led researchers to investigate other antimicrobial therapy approaches. A
potential target is the type II toxin-antitoxin (TA) locus.
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FIG 21 FDA approved antibacterial drugs for use in humans from 1936-2016.
Antibacterial drugs approved by the US Food and Drug Administration (FDA) for use in
humans. This plot shows the number of drugs approved within five-year periods from
1939 until 2017 (all drugs are listed in Table 1 of reference 145). The 157 drugs are
grouped according to 20 classifications as shown by the legend. The greatest number of
drugs were approved between 1981 and 1985. This image is reproduced from reference
145 reviewing FDA approved small molecule drugs, unintended consequences of
antibiotic use, and the development and financial impact of antimicrobial therapy.
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Nontypeable Haemophilus influenzae (NTHi) is a model organism to study one of
the sub-families of the type II TA modules, the vap genes, because it maintains four vap
operons in its very small (~2 Mbp) genome (36). This organism is human-adapted,
meaning that there are no animal or environmental reservoirs for NTHi; it lives exclusively
in humans. This trait has facilitated its evolution as a human commensal, living in the
human upper airway without causing symptoms. Due to this lifestyle, NTHi strains have
lost the genes necessary to synthesize many cofactors such as nicotinamide adenine
dinucleotide (NAD) as well as heme, and scavenges these essential molecules from the
host. Interestingly, however, this bacterium can also cause infections such as otitis
media, bronchitis, and can invade the cerebrospinal fluid (CSF). These infection sites all
vary in the amount of heme and NAD available.
NTHi is one of the leading causes of recurrent otitis media (17), infections that
result in >$4 billion in health-care costs annually (18-20). This study sought to investigate
the prevalence of type II TA modules in many NTHi strains as a potential therapeutic
target. Type II TA loci contribute significantly to the survival and virulence of NTHi during
infections and these loci increase bacterial persistence and dormancy following stress
(36, 60). Due to the increase of antibiotic-resistant NTHi strains and the lack of a suitable
vaccine to prevent these infections, the prevalence and genomic organization of four
important, highly conserved type II TA loci in NTHi, vapBC-1, vapBC-2, vapXD, and
toxAvapA, was investigated in 12 recently-sequenced clinical isolates. It was previously
determined that a single mutation in the conserved region of the PIN domain in VapC-1
causes a significant decrease in survivability of NTHi strain 86-028NP (Fig.13) (143). The
vap genes are part of pathogenicity islands (PAI), that are transferred between organisms
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via horizontal gene transfer (HGT) to help them adapt to new ecological niches (171,
172). Continuing to study TA systems in H. influenzae is a novel way to exploit a potential
antibacterial target. Due to the conservation of type II TA operons, this approach could
be efficacious in the treatment of numerous pathogenic organisms.
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RESULTS
Sequences. Identification and genomic analysis of H. influenzae has evolved from
16S rRNA genes sequencing, DNA-DNA hybridization and multilocus sequence typing
(MLST), to whole-genome sequencing (WGS) facilitated by next-generation sequencing
(NGS) (4, 22, 173-175). In an effort to contribute to genomic studies that have helped
identify genes associated with virulence, growth, persistence, and nutrient acquisition, 12
clinical isolates of NTHi were sequenced (Table 6) on the IlluminaTM MiSeq platform.
Sequence assembly was completed in the Velvet de novo Assembly BaseSpace Labs
application (Illumina) against NTHi strain 86-028NP (NC_007146.2). Strain 86-028NP
(176) was chosen as the reference strain instead of Rd KW20 (168) because Rd is a
laboratory strain with reduced virulence compared to the clinical isolate 86-028NP, and
because 86-028NP has been validated in the chinchilla model of otitis media (177) and
the primary human respiratory tissue model (EpiAirway, AIR 100 ABF; MatTek, Ashland,
MA) (178).
Protein conservation and alignment. The genomes of the 12 recentlysequenced clinical isolates were used to investigate the conservation of type II TA
modules in NTHi. Utilizing the PATRIC Basic Local Alignment Search Tool (BLAST)
service (179), the 12 genomes were queried against the amino acid sequence of the
antitoxin and toxin protein products of the following operons from the reference strain 86028NP: vapBC-1, vapBC-2, vapXD, and toxAvapA (Table 8). The assumption was made
that if the strain had both proteins in an operon, then it maintained the corresponding TA
locus. After determining which isolates maintained the genes that produced the protein
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products listed in Table 8, multiple sequence alignments were performed using Clustal
Omega at EMBL-EBI (180-182) (Fig. 22A to H).

TABLE 6 Sequencing, assembly, and annotation metrics of NTHi strains sequenced on
the MiSeq at Old Dominion University
Strain

C294
C37
C447
C464
C470
R3001
R3168
R3171
R3172
R3175
R3176
R3177

Read
Length
(L)
151
151
151
151
151
151
151
151
151
151
151
151

aN

No. of
aligned
reads (N)a
1,053,389
932,918
965,862
1,030,333
940,232
1,025,145
590,531
552,672
501,645
536,811
532,429
456,581

Coverage
(x)b

Genome
size (bp)

No. of
contigs

83
74
76
81
74
81
47
44
40
42
42
36

1,807,236
1,950,111
1,916,993
1,861,829
1,894,592
1,826,634
1,958,029
1,780,770
1,810,932
1,788,908
1,908,985
1,921,437

79
150
92
142
97
89
144
83
72
102
90
103

= aligned reads for Read 1 and Read 2 combined
= (L X N)/Reference genome bp (1,914,490 bp).
cCoding sequences
bCoverage

Contig
N50
(bp)
92251
36486
59454
60580
57870
72043
91827
101141
79083
74349
114115
67411

G+C
content
(%)
38.1
38.1
38.0
38.0
38.0
37.9
38.2
37.9
38.0
37.9
38.0
38.2

No.
of
CDSc
1842
2038
1951
1916
1922
1830
2002
1761
1791
1781
1955
1988
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TABLE 7 Percent Identity Protein BLAST results against NTHi strain 86-028NP
Protein

a

Strain

VapB-1

VapC-1

VapB-2

VapC-2

VapX

VapD

ToxA

VapA

C294

Xa

Xa

100

100

97

93

100

100

C37

99

97

100

100

Xa

Xa

100

100

C447

Xa

Xa

100

99

97

99

100

100

C464

100

100

100

100

100

100

99

100

C470

100

100

100

99

98

47b

100

100

R3001

99

99

100

100

100

100

100

100

R3168

Xa

Xa

100

99

98

97

100

99

R3171

99

99

100

100

98

49b

100

100

R3172

99

99

100

99

98

47b

100

100

R3175

99

99

100

100

98

49b

99

88

R3176

100

100

100

99

100

100

100

100

R3177

99

99

Xa

Xa

98

99

98

94

Strain is missing the TA locus
Truncation in VapD

b
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vapBC-1. Nine out of the 12 strains maintained the vapBC-1 locus. Three of the
strains (C464, C470, and R3176) shared 100 percent protein identity to the VapB-1
antitoxin (WP_005649046.1) and the VapC-1 toxin (WP_005649049.1) from the
reference strain 86-028NP. The remaining six strains (C37, R3001, R3171, R3172,
R3175, and R3177) were 99 percent identical to the 86-028NP VapB-1 antitoxin. They
shared the same, semi-conservative amino acid change at position 3 (threonine to
alanine). Five strains (R3001, R3171, R3172, R3175, and R3177) had a 99 percent
identity score, and C37 had a 97 percent identity to the 86-028NP VapC-1 toxin. All six
strains shared the same conserved mutation at position 21 (isoleucine to valine) and at
position 36 (methionine to isoleucine). In strain C37, an additional amino acid mutation in
VapC-1 is a conserved mutation at position 93 (arginine to glutamine).
vapBC-2. Eleven of the 12 strains maintain the vapBC-2 locus; strain R3177 is the
only one that does not. The 11 strains shared 100 percent identity to the 86-028NP VapB2 antitoxin (WP_005648011.1). Strains C447, C470, R3168, R3172, and R3176 are 99
percent identical to the 86-028NP VapC-2 toxin (WP_005651560.1) and share the same
non-conservative mutation at position 59 (valine to glycine), with the exception of strain
R3168 which has a semi-conserved mutation at position 17 (arginine to histidine).
vapXD. Eleven of the 12 strains maintain the vapXD locus; strain C37 is the only
one that does not. Three strains, C464, R3001, and R3176 are 100 percent identical to
the 86-028NP VapX antitoxin (WP_011272059.1) and the VapD toxin
(WP_011272058.1). Strains C470, R3168, R3171, R3172, R3175, and R3177 are 98
percent identical to 86-028NP VapX and strains C294 and C447 are 97 percent
identical. All eight strains have a conserved mutation at position 55 (tyrosine to
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histidine) in VapX and the two strains that are 97 percent identical (C294 and C447)
have a semi-conserved mutation at position 36 (valine to alanine). Surprisingly, the
VapD toxin sequence had the most variation. Strains C447 and R3177 are 99 percent
identical and have a semi-conserved mutation at position 23 (glutamic acid to
glutamine). Strain R3168 is 97 percent identical and has the same semi-conserved
mutation at position 23 (glutamic acid to glutamine) as well as a non-conserved
mutation at position 30 (alanine to glutamic acid), and a semi-conserved mutation at
position 31 (valine to threonine). Strain C294 is 93 percent identical and has the semiconserved mutation at position 23 (glutamic acid to glutamine), two deletions at
positions 40 and 41 (threonine and glutamine), a non-conserved mutation at position 48
(methionine to threonine), a conserved mutation at position 61 (alanine to serine), and a
conserved mutation at position 92 (asparagine to serine). Interestingly, four out of the
12 strains (C470, R3171, R3172, and R3175) have a 47 amino acid deletion from
position 30 to 77 that was previously identified in five other strains (85). In addition to
the truncation, strains C470 and R3172 also have the semi-conserved mutation at
position 23 (glutamic acid to glutamine) mutation. Strains R3171 and R3175 have a
non-conserved mutation at position 29 (glycine to arginine).
toxAvapA. This type II TA locus is interesting because unlike the previously
described TAs, toxAvapA (a homologue of the host inhibition of growth locus higBA (183))
is arranged with the toxin directly upstream of the antitoxin. This gene pair exhibits two
promoters, one for the toxin and a second for the antitoxin, a characteristic that likely
contributes to the stability of the antitoxin. All 12 strains maintain the toxAvapA locus.
Eight strains (C294, C37, C447, C470, R3001, R3171, R3172, and R3176) are 100
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percent identical to both the 86-028NP ToxA toxin (WP_005650215.1) and the 86-028NP
VapA antitoxin (WP_005650217.1). Strain C464 is 99 percent identical to ToxA with a
non-conserved mutation at position 59 (leucine to serine). Strain R3175 is also 99 percent
identical with a non-conserved mutation at position 79 (arginine to cysteine). Strain R3177
is 98 percent identical with a semi-conserved mutation at position 23 (threonine to
alanine) and a non-conserved mutation at position 32 (tyrosine to serine). Strain 3168 is
99 percent identical to VapA with a semi-conserved mutation at position 39 (alanine to
valine). Strain R3177 is 94 percent identical to VapA and has 6 mutations: conserved at
position 26 (serine to asparagine); semi-conserved at position 60 (valine to alanine);
conserved at position 79 (aspartic acid to asparagine); non-conserved at position 95
(proline to serine); non-conserved at position 101 (aspartic acid to glycine); and semiconserved at position 104 (threonine to alanine). Interestingly, R3177 has a 13 amino
acid truncation at N-terminus of VapA, however, ToxA is maintained at its full length. A
BLAST search based upon the protein sequence does not reveal any more strains with
this 13 amino acid truncation (179).

86

FIG 22 VapBC-1, VapBC-2, VapXD, and ToxAVapA CLUSTAL O (1.2.4) multiple
sequence alignments (MSA). The protein sequences belonging to four virulence
associated protein (vap) operons from NTHi strain 86-028NP were used to BLAST 12
clinical isolates recently sequenced at Old Dominion University. Strains are listed in the
following order for all MSAs: 86-028NP, C294, C37, C447, C464, C470, R3001, R3168,
R3171, R3172, R3175, R3176, R3177. Strains not included in the alignment are marked
with a caret in the figure legend. MSAs of the following proteins VapB-1 C294^, C447^,
and R3168^ (A); VapC-1 C294^, C447^, and R3168^ (B); VapB-2 R3177^ (C); VapC-2
R3177^ (D); VapX C37^ (E); VapD C37^ (F); ToxA (G); VapA (H). An asterisk indicates
positions which have a single, fully conserved residue; a colon indicates conservation
between groups of strongly similar properties; a period indicates conservation between
groups of weakly similar properties according to the Gonnet PAM 250 matrix. The colors
represent physiological properties of the amino acids: red (small, hydrophobic), blue
(acidic), magenta (basic), green (hydroxyl, sulfhydryl, amine), grey (unusual
amino/imino).
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TA loci organization. By using the protein BLAST service (179), it was
determined that seven of the strains (C454, C470, R3001, R3171, R3172, R3175, and
R3176) had all four vap operons and the remaining five strains (C294, C37, C447, R3168,
and R3177) were missing one operon each. Strains C294, C447, and R3168 were
missing vapBC-1; strain R3177 was missing vapBC-2; and strain 37 was missing vapXD.
The next step was to determine if the four vap loci were located on the genome in the
same region as the reference strain 86-028NP. Location was considered an important
factor because even though NTHi is genetically diverse, the TA loci are important for
bacterial survival and therefore conservation and maintenance are necessary. If the TA
loci were not in the same regions as the reference genome, it could indicate that the
genes were acquired at different times and by different means, such as by horizontal gene
transfer from other microorganisms or from a bacteriophage. A region of one kilobase
directly upstream and downstream of each vap operon was used in the PATRIC BLAST
service (179) to query the 12 recently-sequenced strains to determine if the organization
of the identified operons was the same as the reference sequence (Table 8). It was
determined that all four vap operons shared the same flanking regions as in the reference
strain 86-028NP.
Phylogenetic tree. Phylogenetic trees are important because they can illustrate
evolutionary relationships among biological species. These ancestral relationships can
offer some insight into potential treatments against infections caused by NTHi. For
example, two recently diverged strains would have more nucleotides in common than two
strains from different clades. While a phylogenetic tree will not differentiate what those
similarities and differences are, exploring the genomes and past clinical records of the
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TABLE 8 Operon location BLAST results against a two kilobase region around each
vap operon from 86-028NP
Gene
Strain

vapBC-1

vapBC-2

vapXD

toxAvapA

C294

N/Aa

Conserved

Conserved

Conserved

C37

Conserved

Conserved

Conserved

Conserved

C447

N/Aa

Conserved

Conserved

Conserved

C464

Conserved

Conserved

Conserved

Conserved

C470

Conserved

Conserved

Conserved

Conserved

R3001

Conserved

Conserved

Conserved

Conserved

R3168

N/Aa

Conserved

Conserved

Conserved

R3171

Conserved

Conserved

N/Aa

Conserved

R3172

Conserved

Conserved

Conserved

Conserved

R3175

Conserved

Conserved

Conserved

Conserved

R3176

Conserved

Conserved

Conserved

Conserved

R3177

Conserved

N/Aa

Conserved

Conserved

a

N/A = not available
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strains may provide insight on virulence factors.
The Codon Tree application in PATRIC (184) was used to build two phylogenetic
trees, then upload them into the Interactive Tree of Life (ITOL) (185). The first tree was
built with the 12 clinical isolates recently sequenced at ODU (Fig. 23). This tree was
generated using 1000 protein sequences (a total of 399,105 aligned amino acids) and
953 gene sequences (1,130,649 aligned nucleotides). The second tree included 27
additional H. influenzae sequences collected from GenBank (169) (Table 9). This tree
was generated using 977 protein sequences (a total of 309,629 aligned amino acids) and
900 gene sequences (845,211 aligned nucleotides). Two trees were built using PATRIC
software to observe how the clinical isolates are distributed among a sampling of the H.
influenzae population (Fig. 24). Many of the 27 typeable and nontypeable strains
chosen have been previously studied, and a mixture of invasive and non-invasive strains
was included to investigate the relationship of the recently-sequenced strains to the NTHi
population (Fig. 24).
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FIG 23 Phylogenetic tree of 12 NTHi clinical isolates recently sequenced at Old
Dominion University. The Codon Tree application in PATRIC was used to build a
phylogenetic tree with 12 clinical isolates of NTHi using 1000 protein sequences (a total
of 399,105 aligned amino acids) and 953 gene sequences (1,130,649 aligned
nucleotides). The tree was viewed in iTOL. Only bootstrap values of less than 100 are
reported.
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TABLE 9 Strains used to generate phylogenetic trees
Strain
C294a
C37a

Type
NT
NT

C447a
C464a
C470a
R3001a

NT
NT
NT
NT

R3168a

NT

R3171a

NT

R3172a

NT

R3175a

NT

R3176a

NT

R3177a

NT

2019
60294N1
723
86-028NP

NT
NT
NT
NT

CGSHiCZ412602
NCTC 8143
PitAA
PitEE
PitGG
PitHH
PitII
R2846
R2866

NT
NT
NT
NT
NT
NT
NT
NT
NT

R3021
NML-Hia-1
Hi609
ATCC 10211
10810
NCTC 11394

NT
a
a
b
b
b

Description
Pericardium
Sputum from a patient with
chronic lung disease
Ear
Ear
Ear
Bronchial lavage of a pediatric
cystic fibrosis patient
Blood from Hib vaccinated
patient
Blood from Hib vaccinated
patient
Blood from Hib vaccinated
patient
Blood from Hib vaccinated
patient
Blood from Hib vaccinated
patient
Blood from Hib vaccinated
patient
Sputum
Nasopharyngeal isolate
OME isolate
Nasopharyngeal isolate from a
pediatric OM patient
OME isolate
Type strain (ATCC 33391)
OME isolate
OME isolate
OME isolate
OME isolate
OME isolate
AOM patient
Blood isolate of a child with
meningitis immunized the with
Hib vaccine
22.4-21
Blood isolate
Blood isolate
AMC 36-A-[572]
Isolated from a meningitis patient
Unknown

Source
A.L. Smith
A.L. Smith
A.L. Smith
A.L. Smith
A.L. Smith
A.L. Smith
A.L. Smith
A.L. Smith
A.L. Smith
A.L. Smith
A.L. Smith
A.L. Smith
(186)
(187)
(173)
R.S.
Munson, Jr.

(188)
(188)
(188)
(188)
(188)
A.L. Smith
A.L. Smith

(21)
(189)
(190)
(191)
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TABLE 9 Continued
Strain
Type Description
NCTC 13377
b
Unknown
M12125
c
Unknown
Rd KW20
NT
Type d derivative
Hi467
e
CSF of meningitis patient
KR494
f
Necrotizing myositis
WAPHL1
f
Blood isolate
M21384
hybrid Unknown
NCTC 11426
hybrid Unknown
aStrains sequenced at Old Dominion University

Source

(168)
(192)
(193)
(194)
(195)
(195)
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FIG 24 Phylogenetic tree of 39 strains of H. influenzae. Twelve NTHi clinical isolates
recently sequenced at ODU and 27 typeable and nontypeable invasive and noninvasive
sequenced strains collected from GenBank were used to generate a phylogenetic tree
with the Codon Tree application in PATRIC using 977 protein sequences (a total of
309,629 aligned amino acids) and 900 gene sequences (845,211 aligned nucleotides).
The tree was viewed in iTOL. Only bootstrap values of less than 100 are reported.
Strains highlighted in purple are the 12 isolates recently sequenced at ODU. Strains
highlighted in green are encapsulated strains from the 27 sequences collected from
GenBank. The strains not highlighted are unencapsulated strains from the 27
sequences collected from GenBank.
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DISCUSSION
H. influenzae is a host-adapted human pathogen, and genomic studies have
determined that approximately two-thirds of its proteins have homologues in E. coli.
Most of the genome reduction is due to the loss of paralogues (196). This evolution is
advantageous to an obligate parasite of the human upper respiratory tract because it is
metabolically expensive to maintain duplicate genes or genes that transport and
catabolize products the organism does not need for survival and may never encounter
in its native microenvironment. Encapsulated strains, especially H. influenzae serotype
type b (Hib), are significantly more clonal than NTHi (173, 197-199). This could be the
result of the protective nature of the capsule in typeable strains, which does not facilitate
the acquisition of new DNA via horizontal gene transfer in the DNA-rich environment of
their human hosts. However, NTHi strains are naturally competent, and their high rate of
DNA uptake and homologous recombination significantly influences the genetic diversity
of the species (175, 200). Twelve clinical isolates were sequenced to learn more about
the genetic diversity and to investigate the conservation of four TA loci: vapBC-1,
vapBC-1, vapXD, and toxAvapA.
Trillions of microorganisms cohabitate with their human hosts all over the body in
various anatomical sites (gut, mouth, skin, vagina, upper respiratory tract) (201).
Microbiome and normal flora are terms used to describe this harmonious relationship,
and this niche occupation helps prevent the overgrowth of pathogens. However, stress
imposed on the body, such as that caused by an infection, antibiotic use or a change in
diet, can disrupt the normal flora (202). This disruption can result in both commensal
and opportunistic organisms becoming pathogenic by either increasing in numbers or
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migrating into normally sterile sites and causing infections (203). NTHi is an
opportunistic organism, and a study by Kaur et al. determined no major phylogenetic
differences between asymptomatic colonizing strains and strains that caused acute
otitis media (AOM) (204). Studies have linked TAs to the survival of environmental and
pathogenic bacterial species, which is why it is so important to continue to investigate
the conservation of these operons and exploit them as potential antimicrobial drug
targets (205, 206).
This study sequenced 12 invasive and noninvasive clinical isolates of NTHi from
a range of infection sites in the body including: two sputum, three ear, and seven blood
isolates. Using those sequences and various applications in PATRIC, it was determined
that all 12 isolates had at least three of the four vap operons of interest, and seven of
these strains (58%) maintained all four TAs. In the five strains that maintained three of
the vap operons, vapBC-1 was not maintained in three, vapBC-2 was not maintained in
one, and vapXD was not maintained in one. The percent identity of the antitoxin and
toxin proteins compared to the sequences of strain 86-028NP was often 98-100
percent. Five strains maintained three of the four TAs of interest. Three of these strains
are considered invasive because they infected normally sterile sites (C294, R3168, and
R3177), and two of these strains were considered noninvasive commensals (C37 and
C447). Interestingly, none of the mutations in VapC-1 were in the PilT N-terminal (PIN)
domain (62, 65). The largest difference in the amino acid sequence was a 47 amino
acid deletion in VapD in four of the strains. This unique in-frame deletion was
discovered in ten other clinical strains during a study that identified and characterized
vapXD in 59 commensal and disease-causing isolates NTHi from the nasopharynx,
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sputum/tracheal aspirate/ear, and blood/CSF (85). Daines et al. (2004) determined that
this deletion occurred in 7% of the nasopharynx, 50% of the sputum/tracheal
aspirate/ear, and 29% of the blood/CSF isolates that they sampled. Interestingly, this
deletion occurred in 20% of the sputum/tracheal aspirate/ear, and 43% of the blood
isolates that were sampled. The second sputum isolate that was sequenced did not
maintain the entire vapXD operon. The significance of this truncation is not yet known,
however, future studies to determine its effect on survivability and virulence will allow
investigators to gain insight into the unusual conservation of this in-frame deletion. It
would be interesting to explore the implications of TA loci in invasive, serum-resistant
NTHi strains. Normal human serum is bactericidal, but serum-resistant NTHi prevent the
accumulation of the membrane attack complex (MAC), thus preventing the complement
system from removing the pathogen. The novel system designed to study the vapC-1
mutations in cis (Fig. 12 and 13) could be utilized to compare the survivability of NTHi
expressing either the full length or the truncated VapD toxin gene in the EpiAirway or
chinchilla models.
The genomic location of the TAs based on their flanking one-kilobase regions
were identical, indicating that all 12 strains shared the genomic organization of at least
those four regions, which may be important to the conservation of the operons. This
information continues to support the notion of the necessity for microorganisms to
maintain TAs to facilitate adaptation to changing environments. Future studies to
expand the investigation into the organization of the TA loci with regards to a larger
region in the genome would also be useful for determining any positive or negative
effects on bacterial survival. While it has been determined that virulent epidemic
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bacteria have more TA loci than less virulent bacteria (207), a majority of bacterial
species have between one and five or six to ten type II TA loci (208). NTHi may have
efficiently reduced its genome to coexist with the host as a commensal, but maintained
the necessary genes to survive during times of stress. The importance of these TA loci
to survival and virulence and their high level of conservation provide excellent support
for the approach of targeting these operons to prevent infections caused by non-b
serotypes, NTHi strains, and other pathogens that use this mechanism to survive during
infection.
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MATERIALS AND METHODS
Sequencing. Genomic DNA was extracted from all 12 strains using the Thermo
Scientific GeneJetTM Genomic DNA Purification Kit (Waltham, MA, USA) according to the
manufacturer’s instructions. Sequencing libraries were prepared from genomic DNA
using NexteraTM XT DNA Library Preparation Kit (Illumina, San Diego, CA, USA) and
samples were run separately for sequencing with the MiSeq® 300-cycle micro kit (version
2) on an IlluminaTM MiSeq platform. Trimming and de novo assembly were completed in
the Velvet de novo Assembly BaseSpace Labs application (Illumina) against NTHi strain
86-028NP (NC_007146.2). Automatic annotation was done by Rapid Annotations using
Subsystems Technology (RAST) v2.0 (209, 210) and the Pathosystems Resource
Integration Center (PATRIC) (211) (Table 6). Read 1 and Read 2 were combined to
determine the number of aligned reads. The coverage was calculated with the following
equation (read length (L) x number of aligned reads (N))/reference sequence genome
size (bp). The genome size of strain 86-028NP is 1,914,490 bp (169).
Phylogenetic inference. Twelve clinical isolates sequenced in-house plus an
additional 27 sequenced typeable and nontypeable strain sequences collected from
GenBank (169) were used to generate phylogenetic trees using the Codon Trees function
in PATRIC (184) (Table 10). The Codon Trees function uses amino acid and nucleotide
sequences from PATRIC’s global Protein Families (PGFams) (184). The protein
sequences were aligned using multiple sequence comparison by log-expectation
(MUSCLE) (212), and the nucleotide sequences were aligned using the Codon_align
function of BioPython (213). Randomized Axelerated Maximum Likelihood (RAxML) was
used to analyze and describe the protein and nucleotide alignments (214) and rapid
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bootstrap support values were generated with RAxML software (215). Newick files were
uploaded to the Interactive Tree of Life (ITOL) (185) to view the final product.
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CONCLUSION
These three studies provide insight into the importance of the type II TA loci in
NTHi. In the first study, the crystal structure of VapBC-1 from NTHi was solved in a
collaboration with investigators at the University of Kansas. Utilizing this information,
aspartate-to-asparagine and glutamate-to-glutamine single and double mutations of four
conserved residues in the PIN domain were constructed. Both the homo- and heterointeractions of the mutant VapC-1 toxins in E. coli as well as the mutants’ ability to
cause growth arrest were quantified. All VapC-1 mutants interacted significantly with
themselves (homodimerization) and with wild-type VapB-1 (heterodimerization). Only
one mutant, VapC-1 D99N, caused significant growth arrest in the E. coli assay. The
vapC-1 mutants were expressed with wild-type vapB-1 under the control of the native
vapBC-1 promoter in an infection model utilizing primary human epithelial tissues. It was
determined that a single mutation to the conserved amino acids of the PIN domain
attenuated NTHi survival in this ex vivo model. Not only were the mutant strains
attenuated for survival, they also displayed survival numbers that were not significantly
different from the 86-028NP ΔvapBC-1 knockout that was previously reported (36).
Another important finding was that additional mutations in VapC-1 were not additive.
This result will be helpful in efforts to determine a drug target, because it suggests that
only one small area of the domain needs to be targeted to interfere with ribonuclease
activity. This study was the first to determine the crystal structure of VapBC-1 from NTHi
as well as the first to utilize a model to study TA mutant operons in the background of
NTHi during infections of primary human tissues ex vivo. Promising future steps for this
project include the utilization of in silico docking to find novel targets to inhibit the
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ribonuclease activity of the PIN domain during bacterial infections. Once targets are
determined, these can be characterized in the E. coli growth recovery assay and the
EpiAirways (Fig. 11 and 13) before advancing to the chinchilla model of experimental
otitis media.
The second study designed a growth recovery assay similar to the E. coli model
(Fig. 11) in the background of NTHi strain R2866 (Fig. 18). The toxin was cloned into a
targeted delivery vector with the araC regulatory gene and was fused to the PBAD
promoter to study the induction of vapD in cis in the background of NTHi. E. coli
arabinose permease genes were targeted into the chromosome of NTHi to determine if
their presence increased the transport of arabinose across the membrane (Fig. 18). In
the subsequent growth recovery assay, NTHi did not transport arabinose even with the
help of on of two E. coli arabinose permeases tested in cis. The assay used in the
present study was a good demonstration of the molecular techniques that can be
utilized to study gene expression in NTHi. This study also serves as a reminder that one
of the difficulties of vaccine construction for NTHi is the genetic heterogeneity among
the strains. To successfully complete the assay design, multiple strains had to be used
due to compatibility issues. In future studies, next steps include determining if lack of
induction was due to insufficient amounts of arabinose transport across the membrane.
To measure that, a permease could be cloned into an IPTG-inducible plasmid
compatible in the background of R2866, as it has previously been determined that IPTG
can cross the membrane of NTHi (146).
The third study investigated the prevalence and conservation of type II TA
modules in 12 recently-sequenced NTHi. All 12 strains maintained at least three of the
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four vap genes that were investigated. Type II TA loci contribute significantly to the
survival and virulence of NTHi during infections and these loci increase bacterial
persistence and dormancy following stress. Due to their conservation among strains
and being essential for bacterial survival during infections, these TA loci are an
important potential therapeutic target. Unlike other virulence factors such as antibiotic
resistance genes and protective outer membrane proteins, which can mutate to adapt to
antimicrobial therapy, it would be deleterious for bacteria to mutate these TA loci. Doing
so would ultimately hasten cell death under stressful conditions.
In summary, the lack of newly-identified effective antibiotics increases the need
to explore other non-standard molecular approaches to treat bacterial infections. Due to
the conservation of the type II TA loci, these modules prove to be promising candidates
for the development of a small molecule antimicrobial therapy.
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